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Dear Editors, 
Re:  Ethnic differences in the severity and clinical management of type 2 diabetes at time of diagnosis: A 
cohort study in the UK Clinical Practice Research Datalink
Though marked ethnic differences in the risk of long-term vascular outcomes among people with type 2 
diabetes have been established in UK populations, the extent to which these inequalities stem from modifiable 
factors such as quality of diabetes management have not previously been explored in a large, representative, 
population-based sample. 
In a study funded by the Wellcome Trust, we present a large UK based study to date to examine ethnic 
differences in the clinical characteristics and clinical management of type 2 diabetes around time of initial 
diagnosis. We utilised high quality observational data from the UK CPRD cohort to examine these associations 
in nearly 180,000 UK adults aged 18 and over diagnosed with type 2 diabetes between 2004 and 2017. 
We show that, despite a lower consultation rate and higher burden of diagnosed pre-diabetes, south Asian and 
black African/Caribbean groups have better capture of key risk factors, a lower age at diagnosis, and better or 
equivalent cardio-metabolic profile at diagnosis. Furthermore, following diagnosis, Initiation of antidiabetic 
treatment, diabetes education, and risk assessment is faster for black and south Asian individuals. Overall, our 
findings suggest that downstream inequalities in diabetes outcomes do not appear to stem wholly from 
inequalities around the time of initial diagnosis, and in fact, highlight several positive aspects of primary care-
based diabetes management.
Ethnic differences in the prevalence of diabetes, care and outcomes remains a key area of research worldwide 
has yet to reach its peak. We believe that DRCP would be the ideal place for the dissemination of our study, 
which we believe would be of great interest to your readership.
Thank you for considering our study for publication; we look forward to hearing your decision. 
Yours sincerely 
Rohini Mathur
(On behalf of all authors) 
Assistant Professor in Epidemiology 
London School of Hygiene & Tropical Medicine
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Highlights
 Non-white groups had better or equivalent capture of risk factors prior to 
diagnosis compared to white groups
 Risk factor levels at diagnosis were more favourable for south Asian and 
Black groups
 Initiation of diabetes therapy was faster for non-white groups relative to 
white groups
 Downstream inequalities in type 2 diabetes do not appear to stem from 
inequalities in initial diagnosis
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3Abstract 
Aims: To characterize ethnic differences in the severity and clinical 
management of type 2 diabetes at initial diagnosis. 
Methods: An observational cohort study of 179,886 people with incident type 
2 diabetes between 2004 and 2017 in the Clinical Practice Research Datalink was 
undertaken; 63.4% of the cohort were of white ethnicity, 3.9% south Asian, and 
1.6% black. Ethnic differences in clinical profile at diagnosis, consultation rates, 
and risk factor recording were derived from linear and logistic regression. Cox-
proportional hazards regression was used to determine ethnic differences in time 
to initiation of therapeutic and non-therapeutic management following diagnosis. 
All analyses adjusted for age, sex, deprivation, and clustering by practice.
Results: In the 12 months prior to diagnosis, non-white groups had fewer 
consultations compared to white groups, but risk factor recording was better 
than or equivalent to white groups for 9/10 risk factors for south Asian groups 
and 8/10 risk factors for black groups (p<0.002). Blood pressure, BMI, 
cholesterol, eGFR, and CVD risk levels were more favourable in non-white 
groups, and prevalence of macrovascular disease was significantly lower 
(p<0.003). Time to initiation of antidiabetic treatment and first risk assessment 
was faster in non-white groups relative to white groups, while time to risk factor 
measurement and diabetes review was slower.
Conclusions: We find limited evidence of systematic ethnic inequalities 
around the time of type 2 diabetes diagnosis. Ethnic disparities in downstream 
consequences may relate to genetic risk factors, or manifest later in the care 
pathway, potentially in relation to long-term risk factor control. 
41.0 Introduction
Marked ethnic differences in the risk of long-term vascular outcomes among 
people with type 2 diabetes have been established in UK populations.(1,2) The 
extent to which these inequalities stem from modifiable factors such as 
healthcare usage or quality of diabetes management remains unclear. Given that 
inequalities can accumulate over time, it is vital to identify where along the care 
pathway differences by ethnicity may arise. Though equity of service provision is 
a central tenet of the National Health Service (NHS) (3), recent studies have 
highlighted ethnic differences in access to healthcare, treatment provision and 
risk factor control. (4–8) 
Prior to initial diagnosis, there may be differences in consultation rates and 
measurement of risk factors, which may impact upon the timeliness of diagnosis 
and severity of disease at initial presentation. Delays in diagnosis may result in 
delays in initiation of therapeutic and non-therapeutic management, which may 
further compound existing inequalities. Though guidelines exist for managing 
type 2 diabetes in the UK, the extent to which these are followed may differ by 
ethnic group, leading to inequalities in the downstream consequences of type 2 
diabetes.(8,9). The 2018 UK national diabetes audit identified inequalities by 
age, region, diagnosed serious mental illness and learning disabilities, but did 
not explore differences by ethnicity, leaving a critical gap in the evidence 
base.(10) 
The aims of this study were to (1) Quantify ethnic differences in risk factor levels 
and co-morbidities at the time of initial diagnosis, (2) Compare consultation rates 
and completeness of process of care measures between ethnic groups in the 12 
months preceding type 2 diabetes diagnosis, (3) Determine whether the time to 
initiation of therapeutic and non-therapeutic management following initial 
diagnosis differed by ethnic group.
52.0 Methods
2.1 Study design and population
An observational cohort study utilizing the Clinical Practice Research Datalink 
(CPRD) was undertaken. The CPRD is a clinical research database containing 
anonymised longitudinal primary care records for approximately 15 million 
people from 714 general practices. The CPRD population has been shown to be 
representative of the UK population with respect to age, gender, and 
ethnicity.(11) 
Type 2 diabetes was identified using an adjudication algorithm developed to 
minimize misclassification of diabetes status and type in electronic health 
records. (12) The algorithm assigns an initial diabetes type based on clinical 
Read codes and then applies a series of logic rules to assign a final diabetes 
status by identifying congruent or contradictory evidence on age at diagnosis, 
diabetes complications, and diabetic medications. For individuals with a 
prescription for antidiabetic medication in the 12 months preceding the first ever 
type 2 diabetes diagnosis, the diagnosis date was moved forward to the date of 
prescription as it was deemed plausible that the prescription was related to the 
initial diagnosis. Adults aged 18 and over registered between 2004 and 2017, 
with at least 6 months of continuous registration prior to diagnosis of type 2 
diabetes (the earliest of diagnosis date or medication date where applicable) 
were included in the study. 
62.2 Covariates
Self-reported ethnicity, identified using Read codes, was collapsed into the five 
categories of the 2001 UK census (white, south Asian, black African/Caribbean, 
mixed, and other). For individuals with more than one ethnicity code on their 
primary care record, a previously developed algorithm was used to assign a best 
‘single’ ethnicity – based on the most commonly, and most recently recorded 
codes (Supplementary material, Figure S1).(13) Age at diagnosis was calculated 
by subtracting year of birth from year of diagnosis. Deprivation was measured 
using quintiles of the Index of Multiple Deprivation (IMD). For people with linkage 
to Office for National Statistics data, quintiles of IMD were derived from the 
individual’s home postcode. For the 40% of people without linkage, quintiles 
were derived from the postcode of the individual’s general practice. 
Baseline risk factors were identified from the most recently recorded value in the 
12 months preceding type 2 diabetes diagnosis (see supplementary table S3 for 
all code lists). These included glycated haemoglobin (HbA1c), fasting blood 
glucose (FBG), systolic and diastolic blood pressure (SBP, DBP), body mass index 
(BMI), total cholesterol, serum creatinine, consultations (face-to-face or 
telephone), smoking status ( ‘Ever smoker’, and ‘Never smoker’), alcohol 
consumption ( ‘Non-drinker’, ‘Moderate drinker’, and ‘Heavy drinker’), and family 
history of cardiovascular disease (CVD). Risk assessments included ten-year CVD 
risk and the NHS health check. The CVD risk score, was categorized into “≤ 10% 
risk of developing CVD in the next ten years” and “>10% risk of developing CVD 
in the next ten years”.
Pre-diabetic states included coded pre-diabetes, family history of diabetes, and 
gestational diabetes (for women only). Co-morbidities were considered present 
at baseline if recorded at any time prior to diagnosis.  Macrovascular co-
morbidities included hypertension, coronary heart disease (CHD, including 
7myocardial infarction and angina), stroke, and heart failure. Microvascular co-
morbidities included chronic kidney disease (CKD), retinopathy, and neuropathy. 
To examine diabetes management following initial diagnosis, the date of the first 
antidiabetic medication prescription, consultation, risk factor measurement, 
diabetes review, offer of structured diabetes education, and risk assessment 
following diagnosis was extracted.
2.3 Statistical analysis
As individuals attending the same general practice may have similar levels of 
care provision and clinical coding, multilevel modelling was used to account for 
the clustering of people within practices. Ethnic differences in clinical 
characteristics at diagnosis were derived from multilevel multivariable linear 
regression, (for age at diagnosis, HbA1c, FBG, SBP, DBP, BMI, total cholesterol, 
serum creatinine, and eGFR) and multilevel multivariable logistic regression (for 
deprivation quintile, presence of pre-diabetes, family history of diabetes, 
gestational diabetes, family history of cardiovascular disease, any macrovascular 
disease, any microvascular disease, smoking status, alcohol consumption, CVD 
risk, and use of antihypertensive or lipid lowering drugs) and adjusted for age at 
diagnosis, sex, and deprivation. Multilevel multivariable logistic regression 
adjusted for age at diagnosis, sex, and deprivation was used to determine ethnic 
differences in the odds of having each risk factor recorded in the 12 months prior 
to diagnosis. Multivariable Cox-proportional hazards regression adjusting for age 
at diagnosis, sex, deprivation, raised HbA1c at baseline (>7.5%/53 mmol/L), and 
clustering by practice was used to compare time to initiation of therapeutic and 
non-therapeutic diabetes management between ethnic groups. Follow-up time 
began at the date of type 2 diabetes onset and ended at the earliest of: first 
8antidiabetic prescription or care process, leaving the CPRD, last data collection, 
or death.
2.4 Sensitivity Analysis
We conducted a sensitivity analysis comparing outcomes for those of unknown 
ethnicity to those of any known ethnicity. As recording of ethnicity is a marker of 
engagement with primary care, we hypothesized that individuals with missing 
ethnicity would have poorer risk factor control at diagnosis, lower consultation 
rates, worse capture of risk factors prior to diagnosis and slower initiation of 
therapeutic and non-therapeutic management relative to those with ethnicity 
recorded. 
3.0 Results
From 241,891 individuals diagnosed with type 2 diabetes between April 1st, 2004 
and December 31st, 2016 in the CPRD, 179,886 adults aged 18 or over, with at 
least 6 months registration prior to initial diagnosis, were included in the study 
(Figure 1). Within this population, 5% (n=8,871) had been prescribed an 
antidiabetic medication in the year prior to diagnosis and had their diagnosis 
date moved backwards. Ethnicity was recorded for 70% of the cohort 
(n=126,331), of whom 90.2% were white (n=113,988), 5.5% were south Asian 
(n=6,970), 2.3% were black African/Caribbean (n=2,944), and 1.9% were of 
other ethnicities, including mixed (n=2,409). Comparisons between the white, 
south Asian and black ethnic groups are reported below.  
93.1 Clinical characteristics at initial diagnosis
Crude ethnic differences in clinical characteristics at initial diagnosis are 
described in table 1 and adjusted differences are illustrated in figure 2. After 
adjustment for sex, deprivation, calendar year and clustering by practice, age at 
diagnosis was estimated to be 9.8 years earlier in south Asian groups than white 
groups (95%CI -10.14, -9.45) and 7 years earlier in black groups (95%CI -7.46, -
6.44) relative to white.  Black groups were overrepresented in the least affluent 
deprivation quintile than white groups (OR 1.34, 95%CI 1.20-1.51), while no 
differences in deprivation between white and south Asian groups were evident.
After additionally accounting for age at diagnosis, mean HbA1c was lower in 
south Asian groups 
(β = -1.53, 95%CI -2.29, -0.77) and higher in black groups relative to white 
groups, (β = 1.88 95%CI 0.76- 3.00). BMI, total cholesterol, and eGFR were more 
favourable in non-white groups compared to white groups at diagnosis 
(p<0.001), while fasting blood glucose, blood pressure and creatinine levels were 
better for south Asian groups only (p<0.034). The odds of having co-morbid 
macrovascular disease at diagnosis were reduced in south Asian groups and 
halved in black groups relative to white (South Asian OR 0.88, 95%CI 0.80-0.96, 
Black OR 0.50, 9%CI 0.43-0.58); no ethnic differences in the odds of having 
diagnosed microvascular disease were evident. Furthermore, non-white groups 
had markedly fewer prescriptions of antihypertensive and lipid lowering drugs in 
the 12 months preceding diagnosis, and reduced odds of having a CVD risk score 
over 10% relative to white groups (p<0.007) (Figure 2). 
3.2 Clinical management prior to diagnosis
In the 12 months prior to diagnosis, consultation frequency was higher for white 
groups (median 10, IQR 6-17) than for south Asian (median 9, IQR 5-15) and 
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black groups (median 8, IQR 5-14). After adjustment for age at diagnosis, sex, 
deprivation, and clustering by practice, the consultation rate was significantly 
lower for black groups relative to white ( β = -0.60, 95%I -1.05, -0.21). Risk factor 
recording for south Asian groups was better than or equivalent to non-white 
groups for 9/10 risk factors of interest, and for black groups, risk factor recording 
was better or equivalent for 8/10 risk factors (Table 2).
3.3 Initiation of therapeutic and non-therapeutic management 
following diagnosis
After adjustment for age, sex, deprivation, baseline HbA1c, and clustering by 
practice, time to initiation of antidiabetic therapy was faster south Asian groups  
(HR  1.10, 95%CI 1.07-1.14) and black groups relative to white (HR 1.18, 95%CI 
1.12-1.23). Time to first NHS health check (South Asian HR 1.30, 95%CI 1.10-
1.54, Black HR 1.33, 95%CI 1.6-1.68) and offer of structured diabetes education 
(South Asian HR 1.17, 95%CI 1.10-1.24, Black HR 1.44, 95%CI 1.31-1.56) was 
also faster in south Asian and black groups relative to white. In contrast, time to 
first consultation, risk factor measurement and diabetes review was longer or 
equivalent for both non-white groups relative to white.  (Table 3). 
3.4 Sensitivity analysis
Compared to those of known ethnicity (n=126,331), individuals of unknown 
ethnicity (n=53,575) were younger at diagnosis (β = -1.13, 95%CI -1.32, -0.94) , 
had reduced odds of risk factors recording in the 12 months prior to diagnosis for 
9/10 measures, and slower initiation of therapeutic and non-therapeutic 
management post diagnosis compared to those of known ethnicity (p<0.001). 
While individuals of unknown ethnicity had poorer control of HbA1c, FBG, and 
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blood pressure, they had more favourable cholesterol, BMI and serum creatinine 
levels (p<0.009). Contrary to expectations, individuals of unknown ethnicity had 
greater odds of being in the most affluent quintile of deprivation relative to those 
of known ethnicity (OR 1.14, 95%CI 1.07, 1.21), and a lower prevalence of 
gestational diabetes, vascular disease, and medication use (p<0.001, appendix 
figures S2 S3 , appendix tables S1,S2).
4.0 Discussion
We report the findings of a large population-based cohort study examining ethnic 
differences in both the clinical characteristics and clinical management of type 
two diabetes at time of diagnosis. The results show that, despite a lower 
consultation rate and higher burden of pre-diabetic states, south Asian and black 
groups had better capture of risk factors, a lower age at diagnosis, and better or 
equivalent cardio-metabolic profile at diagnosis. Initiation of antidiabetic 
treatment was faster for black and south Asian individuals, as was time to first 
NHS health check and time to offer of structured education. However, time to 
first consultation and measurement of risk factors was largely slower for non-
white groups. 
Overall, our findings suggest that downstream inequalities in diabetes outcomes 
do not appear to stem wholly from inequalities around the time of initial 
diagnosis, and in fact, highlight several positive aspects of primary care-based 
diabetes management. Firstly, the similarity of microvascular disease between 
ethnic groups at time of diagnosis suggests that non-white groups are not being 
diagnosed at a more severe stage of diabetes progression, and that the latency 
between true onset of diabetes and clinical diagnosis does not disadvantage 
ethnic minority groups. Combined with the findings of pro-active treatment 
initiation and timely risk assessments, our findings suggest that the elevated 
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burden of cardio-metabolic risk in non-white groups is being appropriately 
recognized by health care professionals. Delays in risk factor measurement and 
diabetes review may reflect lower burden of cardio-metabolic risk at time of 
diagnosis or may be indicative of growing ethnic disparities with respect to 
longer-term diabetes management.
4.1 Comparisons with existing literature
To date, only two other UK based studies have reported ethnic differences in 
clinical severity at initial diagnosis of type 2 diabetes.(14,15) The first, a London 
based study of 1,506 individuals, found that  diagnosis was ten years earlier for 
both black and south Asian populations, and that both non-white groups had 
lower levels of glycaemia and vascular complications.(14) The second was a 
2003 survey of 1,899 individuals with type 2 diabetes which reported equivalent 
access to diabetes care between black and white individuals- providing further 
support to our findings of equity between ethnic groups with respect to clinical 
care before and after diagnosis.(15)
Improvements in both quality of diabetes care and risk factor profiles of people 
with type 2 diabetes in the UK may be related to several overlapping causes. 
Firstly, the introduction of the Quality and Outcomes Framework (QOF), which 
incentivises achievement of quality targets for the care of individuals with 
chronic conditions, has both improved overall standards of diabetes care and 
reduced variations in diabetes care provision. (16–18) However, one study found 
that, though QOF incentivisation had accelerated short-term improvements in 
blood pressure and cholesterol, ethnic disparities in HbA1c remained – a finding 
echoed in our own study which showed that black people had significantly higher 
HbA1c at diagnosis, despite equivalence of other risk factors.(19)
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Secondly, awareness amongst health care practitioners about ethnic differences 
in cardio-metabolic risk has increased steadily and may be responsible for the 
pro-active management of diabetes in non-white groups. Ethnicity has now been 
incorporated into clinical guidance documents for hypertension, obesity, type 2 
diabetes, and smoking cessation.(20–22) In May 2018, a new guideline for 
promoting health amongst ethnic minority groups, was published – indicating 
that further reductions in ethnic disparities may become apparent over time.(23) 
Thirdly, improvements in risk factor profiles at diagnosis may be part of a larger 
trend of decreasing vascular disease across the developed world.(24) A 2017 
study of trends in type 2 diabetes incidence, prevalence and mortality in the UK 
found a 32% decrease in all-cause mortality between 2004-2014, and a 2% 
increase in prevalence, thought to be driven by better survival rather than 
increasing incidence.(25) The findings of our study reflect these emerging 
trends, with reductions in ethnic inequalities likely driven by temporal 
improvements in population levels of risk factors, quality of clinical care, 
awareness of established ethnic differences in outcomes, and increased 
effectiveness of novel pharmacological therapies. 
4.3 Strengths 
The strengths and limitations of routine electronic health records (EHRs) for 
diabetes research have been comprehensively outlined in a recent review.(26) In 
this study, the sample size was large and drawn from a representative 
denominator population, allowing sufficient power to detect differences between 
the main ethnic groups in the UK. The cohort was identified using a validated 
algorithm, designed to minimize misclassification of diabetes type.(27)  In order 
to account for the step change in diabetes management following the 
introduction of QOF, entry into the study cohort was restricted to individuals 
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diagnosed with type 2 diabetes from 2004 onwards. Recent improvements in the 
completeness of ethnicity recording in the CPRD as part of QOF have facilitated a 
more robust examination of ethnic differences in conditions managed largely in 
primary care. (13) Linkage to deprivation data enabled us to separate the 
influences of ethnicity and deprivation, which are often conflated when 
examining health disparities. Restricting the study sample to people with at least 
6 months of continuous registration prior to their initial diagnosis of type 2 
diabetes ensured that diagnoses were truly incident and that all outcomes of 
interest were measured as close to initiation of diabetes management as 
possible. General practice characteristics such as size, and participation in local 
enhanced service schemes have been found to play a large role in observed 
variations in quality of diabetes care.(28) By accounting for the clustering of 
people within practices, we were able to appropriately account for the influence 
of practice level factors on ethnic disparities. 
4.2 Limitations
As EHRs are primarily used for patient care rather than research, data quality 
and completeness can vary significantly depending on the time-period, disease 
area, and indicator of interest. Though financial incentivisation has standardized 
many aspects of diabetes care, shared decision is now the preferred model for 
management of many long-term conditions.   As such, observed differences in 
diabetes indicators may be due to active choices by the individual and provider 
to deviate from standard management plans in order to manage competing 
priorities. Ethnicity data was not available for 30% of the study cohort, which 
may have introduced bias. Linkage to other datasets such as the hospital 
episode statistics may have boosted completeness of ethnicity data and allowed 
for better generalizability to UK populations with type 2 diabetes. Since ethnicity 
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data are unlikely to be missing at random, it would have been inappropriate to 
impute these data. Sensitivity analyses showed that individuals with unknown 
ethnicity were younger at diagnosis and, surprisingly, less deprived than those of 
known ethnicity. Coupled with the findings of heterogeneity in clinical profile at 
diagnosis (poorer risk factor levels but fewer co-morbidities), it is likely that this 
is a mixed group encompassing younger, healthier, and more affluent individuals  
who may not need to access healthcare, and individuals who are less healthy, or 
less able to access care. Deprivation scores derived from the postcode of the 
general practice were used for 40% of participants without permissions for 
linkage to individual level data. The relationship between practice level and 
individual level deprivation will vary greatly between individuals, potentially 
underestimating the true confounding effect of deprivation on the association 
between ethnicity and diabetes when using practice level as a proxy.
The dataset did not include information on genetic risk factors, early life 
exposures, migration history, diet and exercise, and thus unmeasured 
confounding may have influenced the results. Future studies combining routine 
EHRs with cohort studies such as the UK Biobank will be valuable in obtaining a 
complete picture of an individual’s health across the life course.
4.4 Conclusions
Overall, we find limited evidence of systematic ethnic inequalities in 
identification of type 2 diabetes and management of cardio-metabolic risk 
around the time of initial diagnosis.  Findings from this study may be illustrative 
of a wider trend of shrinking inequalities in diabetes care. Additional 
investigations into the origin and implications of missingness of ethnicity data 
are warranted. Future work examining the extent to which ethnic differences are 
explained by genetic factors and whether ethnic disparities manifest later in the 
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care pathway, for example, in relation to long-term risk factor control as 
suggested here, will be necessary to understand how patterns of ethnic 
disparities in risk factor control and long-term outcomes are evolving in the UK. 
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*All models adjust for age at diagnosis, sex, deprivation, and clustering by practice
Figure 2. Ethnic differences in clinical severity at type 2 diabetes diagnosis
Table 1. Ethnic differences in clinical characteristics at time of initial Type 2 diabetes diagnosis
  
% 
complete White
South 
Asian Black Other Mixed Unknown
N   113,988 6,970 2,944 1,854 555 53,575
Demographic characteristics Age at diagnosis (mean, SD) 100.0 63.2 (13.4) 52.6 (13.1) 55.1 (13.1) 56.3 (13.2) 54.6 (13.6) 62 (13.4)
 Male, % 100.0
62810 
(55.1) 3767 (54) 1498 (50.9) 1022 (55.1) 304 (54.8)
30643 
(57.2)
 Social Deprivation, % 100.0       
 Quintile 1 (Least deprived)  
20889 
(18.3) 880 (12.6) 169 (5.7) 302 (16.3) 86 (15.5)
11443 
(21.4)
 Quintile 2  
22486 
(19.7) 1081 (15.5) 264 (9) 262 (14.1) 87 (15.7) 8335 (15.6)
 Quintile 3  
25343 
(22.2) 1456 (20.9) 611 (20.8) 368 (19.8) 120 (21.6) 9973 (18.6)
 Quintile 4  
22278 
(19.5) 1605 (23) 820 (27.9) 477 (25.7) 117 (21.1)
13255 
(24.7)
 Quintile 5 (Most deprived)  
22992 
(20.2) 1948 (27.9) 1080 (36.7) 445 (24) 145 (26.1)
10569 
(19.7)
Health behaviours Smoking status, % 72.1       
 Non-Smokers  
32098 
(38.3) 3106 (70.6) 1227 (65.2) 683 (54.6) 189 (49.6)
16406 
(43.2)
 Current Smokers  18479 (22) 701 (15.9) 288 (15.3) 258 (20.6) 100 (26.2) 8037 (21.2)
 Ex-Smokers  
33282 
(39.7) 593 (13.5) 367 (19.5) 311 (24.8) 92 (24.1)
13536 
(35.6)
Risk factor level (mean, SD) HbA1c, mmol/L 52.9 63.2 (22.9) 63.9 (22.7) 66.3 (25) 65 (23.5) 66.6 (24.3) 65.2 (23)
 HbA1c, % 52.9 7.9 (2.1) 8 (2.1) 8.2 (2.3) 8.1 (2.2) 8.2 (2.2) 8.1 (2.1)
 Fasting blood glucose 66.4 10.5 (5) 10.1 (4.7) 10.7 (5.6) 9.9 (4.5) 10.6 (5.3) 10.7 (5.1)
 SBP, mmHg 88.1 142.9 (19.7)
135.5 
(18.7)
140.3 
(19.5)
138.2 
(19.6)
139.2 
(20.5) 143.4 (20.2)
 DBP, mmHg 88.1 82.3 (11.6) 82.3 (11.3) 83.8 (11.4) 82.5 (11) 84 (11.7) 82.9 (11.8)
 BMI, Kg/m2 63.6 32.3 (6.1) 29.7 (5.3) 31.8 (5.9) 30.1 (5.9) 31.3 (6.4) 32.3 (6.1)
 Total cholesterol, mmol/L 78.2 5.2 (1.2) 5.3 (1.2) 5.3 (1.1) 5.3 (1.2) 5.4 (1.2) 5.3 (1.2)
 Serum creatinine, mmol/L 87.0 86.7 (28.6) 78.6 (27.7) 88.5 (42.3) 79.2 (27) 82.4 (25.4) 85.1 (25.9)
 ACR, mg/mmol 2.5 19.6 (46.7) 20.5 (44.3) 15.7 (25.3) 38.1 (70.7) 12.9 (10.8) 20.2 (51.7)
CVD risk score (%) >10% risk in 10 years 17.6 79.1 58.4 50.8 64 53.6 78.3 
Pre-diabetic indicators+ Pre-diabetes  
19007 
(16.7) 1310 (18.8) 496 (16.8) 319 (17.2) 96 (17.3) 8693 (16.2)
 Family history of diabetes  
14471 
(12.7) 1916 (27.5) 659 (22.4) 350 (18.9) 127 (22.9) 5941 (11.1)
 Gestational diabetes*  784 (1.5) 237 (7.4) 72 (5) 41 (4.9) 15 (6) 293 (1.3)
 Family history of CVD  
50813 
(44.6) 2874 (41.2) 858 (29.1) 660 (35.6) 212 (38.2)
23305 
(43.5)
Diagnosed co-morbidities 
(%)+ Any macrovascular disease  
22122 
(19.4) 720 (10.3) 211 (7.2) 184 (9.9) 49 (8.8) 8975 (16.8)
 Any microvascular disease  4781 (4.2) 217 (3.1) 101 (3.4) 49 (2.6) 14 (2.5) 1994 (3.7)
 Hypertension  
57625 
(50.6) 2320 (33.3) 1375 (46.7) 748 (40.3) 222 (40)
26000 
(48.5)
 CHD  
19260 
(16.9) 649 (9.3) 138 (4.7) 162 (8.7) 44 (7.9) 7746 (14.5)
 Stroke  507 (0.4) 12 (0.2) 8 (0.3) 9 (0.5) 0.0 204 (0.4)
 Heart failure  5117 (4.5) 133 (1.9) 90 (3.1) 33 (1.8) 8 (1.4) 2253 (4.2)
 CKD  708 (0.6) 24 (0.3) 16 (0.5) 6 (0.3) 3 (0.5) 267 (0.5)
 Retinopathy  2111 (1.9) 106 (1.5) 56 (1.9) 26 (1.4) 9 (1.6) 979 (1.8)
 Neuropathy  2215 (1.9) 101 (1.4) 38 (1.3) 20 (1.1) 2 (0.4) 845 (1.6)
Medications prescribed (%)+ Antihypertensives  
69988 
(61.4) 2796 (40.1) 1441 (48.9) 838 (45.2) 258 (46.5) 31095 (58)
 Lipid lowering  
52721 
(46.3) 2566 (36.8) 926 (31.5) 729 (39.3) 190 (34.2)
22834 
(42.6)
*Baseline covariate data taken at the date closest to Type 2 diabetes diagnosis in the 12 months preceding diagnosis, (gestational diabetes among women only).
+Pre-diabetic indicators, Diagnosed co-morbidities and medications assumed to be present if recorded and absent if not recorded
Table 2. Risk factor recording and consultations in the 12 months prior to type 2 diabetes diagnosis
 % with risk factor recorded Adjusted difference
  White 
 South 
Asian  Black South Asian vs. White Black vs. White
 N      113,988           6,970           2,944       
 Risk Factors  %   %  % OR 95%CI p.val OR 95%CI p.val
 HbA1c 
             
51.8 
             62.3              
60.9 
1.37 (1.30,1.45) <0.00
1
1.17 (1.08,1.27) <0.00
1
 Glucose 
             
66.2 
             60.8              
59.4 
1.02 (0.97,1.08) 0.455 0.88 (0.81,0.95) 0.002
 Blood Pressure 
             
88.9 
             85.0              
87.0 
0.99 (0.92,1.06) 0.700 1.08 (0.97,1.19) 0.162
 BMI 
             
64.1 
             64.6              
64.6 
0.98 (0.93,1.03) 0.345 1.00 (0.92,1.08) 0.950
 Total Cholesterol 
             
78.9 
             80.8              
78.6 
1.12 (1.06,1.19) <0.00
1
1.01 (0.92,1.09) 0.892
 Creatinine 
             
87.7 
             85.3              
84.9 
1.14 (1.07,1.21) <0.00
1
1.07 (0.97,1.17) 0.163
 Urine ACR                2.4                1.9                2.1 1.18 (0.96,1.44) 0.117 1.18 (0.89,1.57) 0.242
 Smoking Status 
             
73.6 
             63.1              
63.9 
0.72 (0.69,0.76) <0.00
1
0.75 (0.70,0.81) <0.00
1
 Risk assessments          
 NHS Health Check 
               4.1                8.4              
10.2 
1.55 (1.40,1.73) <0.00
1
1.49 (1.29,1.72) <0.00
1
 CVD risk score 
             
18.7 
             22.3              
24.9 
1.05 (0.98,1.12) 0.159 1.22 (1.11,1.35) <0.00
1
Consultations Median (IQR) β CI95% p.val β CI95% p.val
Number of 
consultations
10 (6-17) 9 (5-15) 8 (5-14) -
0.10
(-
0.40,0.18)
0.452 -
0.60
(-1.05,-
0.21)
0.003
*Logistic and linear regression models adjusted for age at baseline, sex, deprivation, and clustering by practice
Table 3. Time to therapeutic and non-therapeutic clinical management following type 2 diabetes diagnosis
 % receiving clinical 
management
Median time to first clinical event 
(months)
Adjusted HR
 White South 
Asian
Black White South 
Asian
Black SA vs. White Black vs. White
N 113,988 6,970 2,944 HR CI95% p.val HR CI95% p.val
First post-diagnosis consultation 99.9 99.7 99.8 0.1 0.1 0.1 0.84 (0.81,0.86) <0.001 0.92 (0.89,0.96) <0.001
 
Initiation of antidiabetic therapy 73.2 80.9 78 3.6 2.2 1.8 1.10 (1.07,1.14) <0.001 1.18 (1.12,1.23) <0.001
 
Risk Factor Measurement
HbA1c 94.8 92.4 89.7 2.7 3.2 3.2 0.93 (0.91,0.96) <0.001 0.88 (0.84,0.91) <0.001
Blood Glucose 61.7 58.1 56.2 10.5 10.3 9.2 0.94 (0.91,0.98) 0.001 0.96 (0.91,1.01) 0.125
Urine ACR 59 53.4 56.4 11.4 12.2 10.6 1.01 (0.98,1.05) 0.504 1.05 (1.00,1.11) 0.055
BMI 92.7 91.2 88.6 1.7 2.1 2.4 0.96 (0.94,0.99) 0.010 0.97 (0.93,1.01) 0.115
Blood Pressure 96.3 94.2 93.5 1.4 1.6 1.4 0.91 (0.88,0.93) <0.001 1.00 (0.96,1.04) 0.872
Total Cholesterol 92.5 90.2 87.6 3.7 4.3 4.1 0.99 (0.97,1.02) 0.667 0.97 (0.93,1.02) 0.220
Smoking Status 93.2 90.4 86.6 3.0 3.4 3.6 0.90 (0.87,0.92) <0.001 0.87 (0.83,0.91) <0.001
Serum Creatinine 94.3 90.7 88.3 3.2 4.0 3.8 0.94 (0.92,0.97) <0.001 0.93 (0.89,0.97) <0.001
 
Diabetes Review
Diabetes Review 82.4 81.1 75.9 6.0 6.7 6.8 1.03 (1.00,1.06) 0.076 1.03 (0.98,1.08) 0.194
Retinopathy Screen 41.1 37.9 41.8 22.8 22.1 19.2 0.98 (0.94,1.02) 0.305 0.93 (0.87,0.98) 0.014
Foot Examination 40 26.9 25.7 26.5 29.8 25.8 0.86 (0.81,0.90) <0.001 0.92 (0.85,0.99) 0.027
Offer of dietary advice 6.3 3.3 1.5 47.6 43.2 38.2 0.81 (0.71,0.94) 0.005 0.64 (0.48,0.87) 0.004
 
Structured diabetes education 
offered 17.2 22.5 25 48.3 40.2 31.0 1.17 (1.10,1.24) <0.001 1.44 (1.32,1.56) <0.001
 
Risk Assessment
CVD risk score 15.4 20.6 18.6 43.4 34.2 30.8 1.02 (0.96,1.09) 0.463 1.06 (0.96,1.16) 0.249
NHS Health Check 1.7 2.8 3.1 52.1 44.9 38.1 1.30 (1.10,1.54) 0.002 1.32 (1.05,1.67) 0.019
*All models adjust for age at baseline, sex, deprivation, raised HbA1c at baseline, and clustering by practice. Time to initiation of antidiabetic therapy restricted to those free from 
antidiabetic medication in 12 months prior to diagnosis date. 
Figure Legends
Figure 1. Study population flowchart 
Figure 2. Ethnic differences in clinical severity at type 2 diabetes diagnosis
Figure S1. Algorithm to assign ethnicity to study participants (This study had access to CPRD data only)
Figure S2: Clinical severity of diabetes at diagnosis for those of known ethnicity compared to those of unknown ethnicity
Table S1. Risk factor recording in the 12 months prior to T2DM diagnosis: Known vs. Unknown ethnicity
% with risk factor 
recorded Adjusted difference
Known Unknown Unknown vs Known
N 126,311 53,575
% % OR 95%CI p.val
HbA1c 52.8 53.0 0.86 (0.83,0.88) <0.001
Glucose 65.7 68.1 0.80 (0.78,0.82) <0.001
Blood Pressure 88.6 87.0 0.76 (0.74,0.79) <0.001
BMI 64.2 62.2 0.84 (0.82,0.87) <0.001
Total Cholesterol 79.0 76.3 0.70 (0.69,0.72) <0.001
Creatinine 87.5 85.9 0.65 (0.63,0.67) <0.001
Urine ACR 2.4 2.8 0.76 (0.96,1.44) 0.117
Smoking Status 72.7 70.9 0.72 (0.69,0.76) <0.001
Risk assessments
NHS Health Check 4.6 2.0 0.81 (0.74,0.89) <0.001
CVD risk score 19.1 14.2 0.78 (0.75,0.82) <0.001
Consultations Median (IQR) β CI95% p.val
Number of 
consultations 10 (6-17) 9 (5-15) -3.00 (-3.14,-2.82) <0.001
Table S2. Time to first clinical management following T2DM diagnosis: Known vs. Unknown ethnicity
 
 
% receiving clinical 
management
Median time to first 
clinical event (months)
Adjusted HR
 Known Unknown Known Unknown Unknown vs Known
  HR CI95% p.val
First post-diagnosis 
consultation 2.6 1.5 50.5 50.4
                         
0.96 
(0.87,1.0
7)
 
0.488 
First antidiabetic 
medication 94.5 93.9 2.8 2.7
                         
0.95 
 
(0.93,0.9
6) 
 
<0.0
01 
Risk Factor Measurement    
Fasting blood glucose 92.2 91 3.8 3.6
                         
0.95 
 
(0.94,0.9
7) 
 
<0.0
01 
HbA1c 92.8 91.9 3.0 2.9
                         
0.91 
(0.90,0.9
3)
 
<0.0
01 
Urine ACR 73.9 72.1 3.4 3.9                          
0.89 
 
(0.87,0.9
1) 
 
<0.0
01
BMI
38.7 34.7 26.7 26.0
                         
0.95 
 
(0.93,0.9
8) 
 
<0.0
01 
Blood Pressure
6 4.8 47.0 47.6
                         
0.99 
(0.92,1.0
6)
 
0.723 
Cholesterol 17.7 17.3 47.2 47.3
                         
0.99 
(0.95,1.0
2)
 
0.438 
Creatinine 15.7 13.2 42.4 44.2
                         
1.05 
(1.01,1.0
9)
 
0.025 
CVD Risk score 1.8 .6 51.1 51.0
                         
0.65 
 
(0.55,0.7
5) 
 
<0.0
01 
    
Diabetes Review    
Dietary Advice 99.9 99.8 0.1 0.1
                         
0.91 
 
(0.89,0.9
2) 
 
<0.0
01 
Diabetes review 61.3 65.3 10.4 8.0
                         
0.92 
 
(0.90,0.9
4) 
 
<0.0
01 
Retinopathy screen 58.6 67.1 11.4 8.0
                         
0.90 
 
(0.88,0.9
2) 
 
<0.0
01 
Foot examination 96.1 95.7 1.4 1.4
                         
0.93 
 
(0.91,0.9
4) 
 
<0.0
01 
    
Structured diabetes 
education offered 92.5 91.4 1.8 1.7
                         
0.91 
 
(0.90,0.9
2) 
 
<0.0
01 
    
Risk Assessment    
CVD risk score 1.8 .6 51.1 51.0
                         
0.65 
 
(0.55,0.7
5) 
 
<0.0
01 
NHS Health Check 93.9 93.3 3.3 3.1
                         
0.92 
 
(0.91,0.9
4) 
 
<0.0
01 
*All models adjust for age at baseline, sex, deprivation, raised HbA1c at baseline, and clustering by practice. Time to initiation of antidiabetic therapy restricted to those 
free from antidiabetic medication in 12 months prior to diagnosis date
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Figure S3. Correspondence analysis plot obtained from the contingency table cross-classifying ethnicity and IMD deprivation quintile
Notes: Correspondence analysis allows visualisation of relationships between two categorical variables in a two-dimensional biplot whereby a measure of association of 
categories of the two variables (ethnicity and deprivation) is given by the inner product of the vectors that link them to the origin. The distance of the profile points of 
deprivation and ethnicity from the origin defines their distance from the average socio-economic and ethnic profile. CA biplots capturing 99.4% of the dispersion in the data 
show a strong association between Black, South-Asian, Mixed and Other groups and the 5th quintile of deprivation (their distance from the origin is large/moderate and the 
angle between them acute/negligible). The white group appears to be associated with the second and third quintiles of deprivation, although less strongly as they are closer 
to the origin (i.e. the average deprivation profile). The group of unknown ethnicity appears to be associated with both the 4th and 1st quintile of deprivation (moderate 
distance from the origin and acute angle with both quintiles), suggesting this group has a more heterogenous socio-economic composition.   
Table S3. Codelists for all study variables
CPRD Medcode Readcode Readterm
Ethnicity Ethnicity in 16 
categories
Ethnicity in 5 
cateories
10196 9S...00 Ethnic groups (1991 census) Not Stated Not Stated
22467 9S1..00 White British White
12446 9S10.00 White British British White
24837 9S11.00 White Irish Irish White
12444 9S12.00 Other white ethnic group Other White White
26467 9S13.00 White Scottish Other White White
26310 9S14.00 Other white British ethnic group British White
12632 9S2..00 Black Caribbean Caribbean Black
12778 9S3..00 Black African African Black
24339 9S4..00 Black, other, non-mixed origin Other Black Black
12452 9S41.00 Black British Other Black Black
57435 9S42.00 Black Caribbean/W.I./Guyana Other Black Black
47950 9S42.11 Black Caribbean Other Black Black
47997 9S42.12 Black West Indian Other Black Black
32100 9S42.13 Black Guyana Other Black Black
41329 9S43.00 Black N African/Arab/Iranian Other Black Black
46812 9S43.11 Black North African Other Black Black
57752 9S43.12 Black Arab Other Black Black
50286 9S43.13 Black Iranian Other Black Black
35412 9S44.00 Black - other African country African Black
47965 9S45.00 Black E Afric Asia/Indo-Caribb Other Black Black
57753 9S45.11 Black East African Asian Other Black Black
57763 9S45.12 Black Indo-Caribbean Other Black Black
48005 9S46.00 Black Indian sub-continent Other Black Black
35350 9S47.00 Black - other Asian Other Black Black
26312 9S48.00 Black Black - other Other Black Black
25676 9S5..00 Black - other, mixed Other Black Black
25623 9S51.00 Other Black - Black/White orig Other Mixed Mixed
32165 9S52.00 Other Black - Black/Asian orig Other Mixed Mixed
12482 9S6..00 Indian Indian South Asian
24690 9S7..00 Pakistani Pakistani South Asian
24740 9S8..00 Bangladeshi Bangladeshi South Asian
24272 9S9..00 Chinese Chinese Other
30280 9SA..00 Other ethnic non-mixed (NMO) Other ethnic group Other
32110 9SA1.00 Brit. ethnic minor. spec.(NMO) Other ethnic group Other
57764 9SA2.00 Brit. ethnic minor. unsp (NMO) Other ethnic group Other
54593 9SA3.00 Caribbean I./W.I./Guyana (NMO) Other Black Black
57094 9SA3.11 Caribbean Island (NMO) Other Black Black
57075 9SA3.12 West Indian (NMO) Other Black Black
93144 9SA3.13 Guyana (NMO) Other Black Black
24962 9SA4.00 N African Arab/Iranian (NMO) Other ethnic group Other
47285 9SA4.11 North African Arab (NMO) Other ethnic group Other
25082 9SA4.12 Iranian (NMO) Other ethnic group Other
47969 9SA5.00 Other African countries (NMO) African Black
38097 9SA6.00 E Afric Asian/Indo-Carib (NMO) Other Asian South Asian
46818 9SA6.11 East African Asian (NMO) Other Asian South Asian
99316 9SA6.12 Indo-Caribbean (NMO) Other Asian South Asian
39696 9SA7.00 Indian sub-continent (NMO) Other Asian South Asian
26379 9SA8.00 Other Asian (NMO) Other Asian South Asian
24270 9SA9.00 Irish (NMO) Irish White
45947 9SAA.00 Greek/Greek Cypriot (NMO) Other ethnic group Other
45955 9SAA.11 Greek (NMO) Other ethnic group Other
47949 9SAA.12 Greek Cypriot (NMO) Other ethnic group Other
32066 9SAB.00 Turkish/Turkish Cypriot (NMO) Other ethnic group Other
32126 9SAB.11 Turkish (NMO) Other ethnic group Other
32069 9SAB.12 Turkish Cypriot (NMO) Other ethnic group Other
12633 9SAC.00 Other European (NMO) Other ethnic group Other
41214 9SAD.00 Other ethnic NEC (NMO) Other ethnic group Other
12696 9SB..00 Other ethnic, mixed origin Other Mixed Mixed
47401 9SB1.00 Other ethnic, Black/White orig Other Mixed Mixed
32401 9SB2.00 Other ethnic, Asian/White orig White and Asian Mixed
35459 9SB3.00 Other ethnic, mixed white orig Other Mixed Mixed
32420 9SB4.00 Other ethnic, other mixed orig Other Mixed Mixed
32425 9SB5.00 Black Caribbean and White White and Black 
Caribbean
Mixed
32443 9SB6.00 Black African and White White and Black 
African
Mixed
25411 9SC..00 Vietnamese Other ethnic group Other
12429 9SD..00 Ethnic group not given - patient refused Not Stated Not Stated
24340 9SE..00 Ethnic group not recorded Not Stated Not Stated
32136 9SG..00 Other black ethnic group Other Black Black
12668 9SH..00 Other Asian ethnic group Other Asian South Asian
47601 9SI..00 Irish traveller Irish White
12757 9SJ..00 Other ethnic group Other ethnic group Other
45199 9SZ..00 Ethnic groups (census) NOS Not Stated Not Stated
12435 9i...00 Ethnic category - 2001 census Not Stated Not Stated
12351 9i0..00 British or mixed British - ethnic category 
2001 census
British White
98111 9i00.00 White British - ethnic category 2001 
census
British White
12532 9i1..00 Irish - ethnic category 2001 census Irish White
98213 9i10.00 White Irish - ethnic category 2001 census Irish White
12421 9i2..00 Other White background - ethnic 
category 2001 census
Other White White
12352 9i20.00 English - ethnic category 2001 census Other White White
12436 9i21.00 Scottish - ethnic category 2001 census Other White White
12681 9i22.00 Welsh - ethnic category 2001 census Other White White
28887 9i23.00 Cornish - ethnic category 2001 census Other White White
42294 9i24.00 Northern Irish - ethnic category 2001 
census
Other White White
40102 9i25.00 Ulster Scots - ethnic category 2001 
census
Other White White
32778 9i26.00 Cypriot (part not stated) - ethnic 
category 2001 census
Other White White
12355 9i27.00 Greek - ethnic category 2001 census Other White White
12769 9i28.00 Greek Cypriot - ethnic category 2001 
census
Other White White
12746 9i29.00 Turkish - ethnic category 2001 census Other White White
32413 9i2A.00 Turkish Cypriot - ethnic category 2001 
census
Other White White
12412 9i2B.00 Italian - ethnic category 2001 census Other White White
55223 9i2C.00 Irish Traveller - ethnic category 2001 
census
Other White White
55113 9i2D.00 Traveller - ethnic category 2001 census Other White White
42290 9i2E.00 Gypsy/Romany - ethnic category 2001 
census
Other White White
12467 9i2F.00 Polish - ethnic category 2001 census Other White White
12433 9i2G.00 Baltic Estonian/Latvian/Lithuanian - ethn 
categ 2001 census
Other White White
28973 9i2H.00 Commonwealth (Russian) Indep States - 
ethn categ 2001 census
Other White White
26341 9i2J.00 Kosovan - ethnic category 2001 census Other White White
25422 9i2K.00 Albanian - ethnic category 2001 census Other White White
46956 9i2L.00 Bosnian - ethnic category 2001 census Other White White
28866 9i2M.00 Croatian - ethnic category 2001 census Other White White
47074 9i2N.00 Serbian - ethnic category 2001 census Other White White
28936 9i2P.00 Other republics former Yugoslavia - 
ethnic categ 2001 census
Other White White
26391 9i2Q.00 Mixed Irish and other White - ethnic 
category 2001 census
Other White White
12402 9i2R.00 Oth White European/European 
unsp/Mixed European 2001 census
Other White White
28900 9i2S.00 Other mixed White - ethnic category 
2001 census
Other White White
12591 9i2T.00 Other White or White unspecified ethnic 
category 2001 census
Other White White
12742 9i3..00 White and Black Caribbean - ethnic 
category 2001 census
White and Black 
Caribbean
Mixed
12437 9i4..00 White and Black African - ethnic category 
2001 census
White and Black 
African
Mixed
12638 9i5..00 White and Asian - ethnic category 2001 
census
White and Asian Mixed
12873 9i6..00 Other Mixed background - ethnic 
category 2001 census
Other Mixed Mixed
12795 9i60.00 Black and Asian - ethnic category 2001 
census
Other Mixed Mixed
49940 9i61.00 Black and Chinese - ethnic category 2001 
census
Other Mixed Mixed
40110 9i62.00 Black and White - ethnic category 2001 
census
Other Mixed Mixed
12706 9i63.00 Chinese and White - ethnic category 
2001 census
Other Mixed Mixed
47005 9i64.00 Asian and Chinese - ethnic category 2001 
census
Other Mixed Mixed
32408 9i65.00 Other Mixed or Mixed unspecified ethnic 
category 2001 census
Other Mixed Mixed
12414 9i7..00 Indian or British Indian - ethnic category 
2001 census
Indian South Asian
12460 9i8..00 Pakistani or British Pakistani - ethnic 
category 2001 census
Pakistani South Asian
28888 9i9..00 Bangladeshi or British Bangladeshi - ethn 
categ 2001 census
Bangladeshi South Asian
12513 9iA..00 Other Asian background - ethnic 
category 2001 census
Other Asian South Asian
26392 9iA1.00 Punjabi - ethnic category 2001 census Other Asian South Asian
64133 9iA2.00 Kashmiri - ethnic category 2001 census Other Asian South Asian
47077 9iA3.00 East African Asian - ethnic category 2001 
census
Other Asian South Asian
12608 9iA4.00 Sri Lankan - ethnic category 2001 census Other Asian South Asian
12760 9iA5.00 Tamil - ethnic category 2001 census Other Asian South Asian
12887 9iA6.00 Sinhalese - ethnic category 2001 census Other Asian South Asian
32399 9iA7.00 Caribbean Asian - ethnic category 2001 
census
Other Asian South Asian
12653 9iA8.00 British Asian - ethnic category 2001 
census
Other Asian South Asian
46056 9iA9.00 Mixed Asian - ethnic category 2001 
census
Other Asian South Asian
28935 9iAA.00 Other Asian or Asian unspecified ethnic 
category 2001 census
Other Asian South Asian
12432 9iB..00 Caribbean - ethnic category 2001 census Caribbean Black
12350 9iC..00 African - ethnic category 2001 census African Black
32389 9iD..00 Other Black background - ethnic category 
2001 census
Other Black Black
12443 9iD0.00 Somali - ethnic category 2001 census Other Black Black
32886 9iD1.00 Nigerian - ethnic category 2001 census Other Black Black
40097 9iD2.00 Black British - ethnic category 2001 
census
Other Black Black
40096 9iD3.00 Mixed Black - ethnic category 2001 
census
Other Black Black
46047 9iD4.00 Other Black or Black unspecified ethnic 
category 2001 census
Other Black Black
12468 9iE..00 Chinese - ethnic category 2001 census Chinese Other
12434 9iF..00 Other - ethnic category 2001 census Other ethnic group Other
12719 9iF0.00 Vietnamese - ethnic category 2001 
census
Other ethnic group Other
12473 9iF1.00 Japanese - ethnic category 2001 census Other ethnic group Other
12420 9iF2.00 Filipino - ethnic category 2001 census Other ethnic group Other
12730 9iF3.00 Malaysian - ethnic category 2001 census Other ethnic group Other
63872 9iF4.00 Buddhist - ethnic category 2001 census Other ethnic group Other
56127 9iF5.00 Hindu - ethnic category 2001 census Other ethnic group Other
46063 9iF6.00 Jewish - ethnic category 2001 census Other ethnic group Other
47091 9iF7.00 Muslim - ethnic category 2001 census Other ethnic group Other
49658 9iF8.00 Sikh - ethnic category 2001 census Other ethnic group Other
46059 9iF9.00 Arab - ethnic category 2001 census Other ethnic group Other
47028 9iFA.00 North African - ethnic category 2001 
census
Other ethnic group Other
28909 9iFB.00 Mid East (excl Israeli, Iranian & Arab) - 
eth cat 2001 cens
Other ethnic group Other
46964 9iFC.00 Israeli - ethnic category 2001 census Other ethnic group Other
25937 9iFD.00 Iranian - ethnic category 2001 census Other ethnic group Other
45964 9iFE.00 Kurdish - ethnic category 2001 census Other ethnic group Other
25451 9iFF.00 Moroccan - ethnic category 2001 census Other ethnic group Other
26246 9iFG.00 Latin American - ethnic category 2001 
census
Other ethnic group Other
12756 9iFH.00 South and Central American - ethnic 
category 2001 census
Other ethnic group Other
32382 9iFJ.00 Mauritian/Seychellois/Maldivian/St 
Helena eth cat 2001census
Other ethnic group Other
26455 9iFK.00 Any other group - ethnic category 2001 
census
Other ethnic group Other
12459 9iG..00 Ethnic category not stated - 2001 census Not Stated Not Stated
Type 2 diabetes
C10FL Definite T2 codes
C10F4 Definite T2 codes
C10F6 Definite T2 codes
C10FQ Definite T2 codes
C10FP Definite T2 codes
C10F9 Definite T2 codes
C10FG Definite T2 codes
C10FH Definite T2 codes
C10FK Definite T2 codes
C10FJ Definite T2 codes
C10FD Definite T2 codes
C10FR Definite T2 codes
C10FA Definite T2 codes
C10FN Definite T2 codes
C10F3 Definite T2 codes
C10F5 Definite T2 codes
C10FC Definite T2 codes
C10F. Definite T2 codes
C10F2 Definite T2 codes
C10F1 Definite T2 codes
C10FM Definite T2 codes
C10F0 Definite T2 codes
C10FB Definite T2 codes
C10FE Definite T2 codes
C10FF Definite T2 codes
C10F7 Definite T2 codes
C1071 Possible T2 codes
C1051 Possible T2 codes
C1041 Possible T2 codes
C1072 Possible T2 codes
C112z Possible T2 codes
C112. Possible T2 codes
L180X Possible T2 codes
C1021 Possible T2 codes
C1031 Possible T2 codes
C1061 Possible T2 codes
C1001 Possible T2 codes
L1806 Probable T2 codes
C1099 Probable T2 codes
C109J Probable T2 codes
C1090 Probable T2 codes
C109E Probable T2 codes
C109G Probable T2 codes
C109. Probable T2 codes
C1097 Probable T2 codes
C109D Probable T2 codes
C1095 Probable T2 codes
C1091 Probable T2 codes
C109H Probable T2 codes
C1096 Probable T2 codes
C109B Probable T2 codes
C1074 Probable T2 codes
C1094 Probable T2 codes
C109C Probable T2 codes
C109K Probable T2 codes
C1093 Probable T2 codes
C10y1 Probable T2 codes
C1092 Probable T2 codes
C10z1 Probable T2 codes
C109F Probable T2 codes
C109A Probable T2 codes
Diet control
7563 66A3.00 Diabetic on diet only
Smoking status
medcode readcode readterm
33 1371.00 Never smoked tobacco
54 137..00 Tobacco consumption
60 137L.00 Current non-smoker
90 137S.00 Ex smoker
93 137P.00 Cigarette smoker
776 137K.00 Stopped smoking
1822 1376.00 Very heavy smoker - 40+cigs/d
1823 137P.11 Smoker
1878 1374.00 Moderate smoker - 10-19 cigs/d
3568 1375.00 Heavy smoker - 20-39 cigs/day
10558 137R.00 Current smoker
11788 1371.11 Non-smoker
12240 137G.00 Trying to give up smoking
12878 137T.00 Date ceased smoking
12941 1372.11 Occasional smoker
12942 137..11 Smoker - amount smoked
12943 137J.00 Cigar smoker
12944 1373.00 Light smoker - 1-9 cigs/day
12945 137M.00 Rolls own cigarettes
12946 137F.00 Ex-smoker - amount unknown
12947 137H.00 Pipe smoker
12951 137Q.11 Smoking restarted
12952 137Q.00 Smoking started
12955 1379.00 Ex-moderate smoker (10-19/day)
12956 137A.00 Ex-heavy smoker (20-39/day)
12957 1378.00 Ex-light smoker (1-9/day)
12958 1372.00 Trivial smoker - < 1 cig/day
12959 137B.00 Ex-very heavy smoker (40+/day)
12960 137Z.00 Tobacco consumption NOS
12961 1377.00 Ex-trivial smoker (<1/day)
12962 137E.00 Tobacco consumption unknown
12963 137Y.00 Cigar consumption
12964 137C.00 Keeps trying to stop smoking
12965 137X.00 Cigarette consumption
12966 137V.00 Smoking reduced
12967 137a.00 Pipe tobacco consumption
13351 137I.00 Passive smoker
19488 137O.00 Ex cigar smoker
23017 137U.00 Not a passive smoker
26470 137N.00 Ex pipe smoker
30423 137c.00 Thinking about stopping smoking
30762 137d.00 Not interested in stopping smoking
31114 137b.00 Ready to stop smoking
32973 137W.00 Chews tobacco
41979 137e.00 Smoking restarted
46300 137g.00 Cigarette pack-years
46321 137f.00 Reason for restarting smoking
46654 137D.00 Admitted tobacco cons untrue ?
62686 137h.00 Minutes from waking to first tobacco 
consumption
97029 137k.00 Refusal to give smoking status
97210 137j.00 Ex-cigarette smoker
99838 137K000 Recently stopped smoking
100495 137l.00 Ex roll-up cigarette smoker
101069 137I000 Exposed to tobacco smoke at home
101338 137m.00 Failed attempt to stop smoking
105501 137o.00 Waterpipe tobacco consumption
105711 137n.00 Total time smoked
106891 137i.00 Ex-tobacco chewer
Creatinine (for eGFR)
5 44J3.00 Serum creatinine
14563 46W..00 Urine microalbumin
3927 44J3300 Serum creatinine raised
9430 4679.00 Urine dipstick for protein
13736 44JF.00 Plasma creatinine level
13735 44HG.00 Serum creatine kinase level
31277 44J3000 Serum creatinine abnormal
26903 44J3200 Serum creatinine normal
35545 44J3100 Serum creatinine low
62062 44JC.00 Corrected plasma creatinine level
42345 44J3z00 Serum creatinine NOS
45096 44JD.00 Corrected serum creatinine level
Alcohol consumption
medcode readcode readterm
385 1362.11 Drinks rarely
669 E250000 Nondependent alcohol abuse, 
unspecified
749 1362.12 Drinks occasionally
956 136J.00 Social drinker
967 1367 Stopped drinking alcohol
1399 E23..12 Alcohol problem drinking
1618 1365.00 Heavy drinker - 7-9u/day
2689 136G.00 Beer drinker
3782 E250.14 Intoxication - alcohol
4447 1361.12 Non-drinker alcohol
7746 E250.00 Nondependent alcohol abuse
8999 136P.00 Heavy drinker
9169 R103.00 [D]Alcohol blood level excessive
10161 2577.11 O/E - alcoholic breath
12271 E250.11 Drunkenness NOS
12949 1361 Teetotaller
12968 136H.00 Drinks beer and spirits
12969 136I.00 Drinks wine
12970 1361.11 Non drinker alcohol
12971 136F.00 Spirit drinker
12972 1363.00 Light drinker - 1-2u/day
12974 E250200 Nondependent alcohol abuse, episodic
12975 1362.00 Trivial drinker - <1u/day
12977 1366.00 Very heavy drinker - >9u/day
12979 136M.00 Current non drinker
12980 136N.00 Light drinker
12982 136K.00 Alcohol intake above recommended 
sensible limits
12983 136E.00 Ex-very heavy drinker-(>9u/d)
12984 136Q.00 Very heavy drinker
12985 136O.00 Moderate drinker
16587 ZV11311 [V]Problems related to lifestyle alcohol 
use
17777 E250.13 Inebriety NOS
19401 136R.00 Binge drinker
19493 136D.00 Ex-heavy drinker - (7-9u/day)
19494 136S.00 Hazardous alcohol use
19495 136C.00 Ex-moderate drinker - (3-6u/d)
22933 136A.00 Ex-trivial drinker (<1u/day)
23610 E250100 Nondependent alcohol abuse, 
continuous
23978 U81..00 [X]Evid of alcohol involv determind by 
level of intoxication
24735 2577 O/E - breath - alcohol smell
26471 136B.00 Ex-light drinker - (1-2u/day)
26472 136L.00 Alcohol intake within recommended 
sensible limits
27518 E250.12 Hangover (alcohol)
28150 E250z00 Nondependent alcohol abuse NOS
30695 136T.00 Harmful alcohol use
31569 E250300 Nondependent alcohol abuse in 
remission
44783 1D19.00 Pain in lymph nodes after alcohol 
consumption
84218 13ZY.00 Disqualified from driving due to excess 
alcohol
94670 136W.00 Alcohol misuse
Coronary Heart Disease (QOF 
Definition)
240 G3...00 Ischaemic heart disease
241 G30..00 Acute myocardial infarction
1204 G30..14 Heart attack
1344 G340.12 Coronary artery disease
1414 G33z300 Angina on effort
1430 G33..00 Angina pectoris
1431 G311.13 Unstable angina
1655 G340.11 Triple vessel disease of the heart
1676 G3z..00 Ischaemic heart disease NOS
1677 G30..15 MI - acute myocardial infarction
1678 G308.00 Inferior myocardial infarction NOS
1792 G3...13 IHD - Ischaemic heart disease
2491 G30..12 Coronary thrombosis
3704 G307.00 Acute subendocardial infarction
3999 G340000 Single coronary vessel disease
4017 G32..00 Old myocardial infarction
4656 G311.11 Crescendo angina
5254 G340100 Double coronary vessel disease
5387 G301.00 Other specified anterior myocardial 
infarction
5413 G340.00 Coronary atherosclerosis
7320 G343.00 Ischaemic cardiomyopathy
7347 G311100 Unstable angina
7696 G33z200 Syncope anginosa
8935 G302.00 Acute inferolateral infarction
9276 G31y000 Acute coronary insufficiency
9413 G31y.00 Other acute and subacute ischaemic 
heart disease
9507 G307000 Acute non-Q wave infarction
9555 G33z500 Post infarct angina
10562 G307100 Acute non-ST segment elevation 
myocardial infarction
11983 G311500 Acute coronary syndrome
12139 G300.00 Acute anterolateral infarction
12229 G30X000 Acute ST segment elevation myocardial 
infarction
12804 G33z700 Stable angina
13566 G30..11 Attack - heart
13571 G30..16 Thrombosis - coronary
14658 G30z.00 Acute myocardial infarction NOS
14897 G301z00 Anterior myocardial infarction NOS
14898 G305.00 Lateral myocardial infarction NOS
15754 G34z.00 Other chronic ischaemic heart disease 
NOS
16408 G32..11 Healed myocardial infarction
17307 G311200 Angina at rest
17464 G32..12 Personal history of myocardial infarction
17689 G30..17 Silent myocardial infarction
17872 G301100 Acute anteroseptal infarction
18118 G311400 Worsening angina
18125 G330000 Nocturnal angina
18842 G35..00 Subsequent myocardial infarction
18889 G34z000 Asymptomatic coronary heart disease
19655 G311.14 Angina at rest
20095 G330.00 Angina decubitus
20416 G3...12 Atherosclerotic heart disease
21844 G31y300 Transient myocardial ischaemia
22383 G3y..00 Other specified ischaemic heart disease
23078 G34y100 Chronic myocardial ischaemia
23892 G304.00 Posterior myocardial infarction NOS
24540 G34y000 Chronic coronary insufficiency
24783 G3...11 Arteriosclerotic heart disease
25842 G33z.00 Angina pectoris NOS
26863 G33z600 New onset angina
27951 G31..00 Other acute and subacute ischaemic 
heart disease
27977 G31yz00 Other acute and subacute ischaemic 
heart disease NOS
28138 G34..00 Other chronic ischaemic heart disease
28554 G33zz00 Angina pectoris NOS
28736 G30y000 Acute atrial infarction
29421 G344.00 Silent myocardial ischaemia
29643 G303.00 Acute inferoposterior infarction
29758 G30X.00 Acute transmural myocardial infarction 
of unspecif site
29902 G330z00 Angina decubitus NOS
30330 G309.00 Acute Q-wave infarct
30421 G30..13 Cardiac rupture following myocardial 
infarction (MI)
32272 G38..00 Postoperative myocardial infarction
32450 G33z400 Ischaemic chest pain
32854 G30B.00 Acute posterolateral myocardial 
infarction
34328 G311300 Refractory angina
34633 G34y.00 Other specified chronic ischaemic heart 
disease
34803 G30y.00 Other acute myocardial infarction
35713 G34yz00 Other specified chronic ischaemic heart 
disease NOS
36523 G311.00 Preinfarction syndrome
36609 G342.00 Atherosclerotic cardiovascular disease
38609 G351.00 Subsequent myocardial infarction of 
inferior wall
39449 G312.00 Coronary thrombosis not resulting in 
myocardial infarction
39546 Gyu3000 [X]Other forms of angina pectoris
39655 G311.12 Impending infarction
39693 G31y200 Subendocardial ischaemia
40429 G301000 Acute anteroapical infarction
41221 G30y200 Acute septal infarction
41835 G384.00 Postoperative subendocardial 
myocardial infarction
45809 G350.00 Subsequent myocardial infarction of 
anterior wall
46017 G30yz00 Other acute myocardial infarction NOS
46112 G380.00 Postoperative transmural myocardial 
infarction anterior wall
46166 G35X.00 Subsequent myocardial infarction of 
unspecified site
46276 G381.00 Postoperative transmural myocardial 
infarction inferior wall
47637 Gyu3300 [X]Other forms of chronic ischaemic 
heart disease
52517 Gyu3.00 [X]Ischaemic heart diseases
54251 G311z00 Preinfarction syndrome NOS
54535 G33z100 Stenocardia
55137 G311011 MI - myocardial infarction aborted
61072 G311000 Myocardial infarction aborted
62626 G30y100 Acute papillary muscle infarction
63467 G306.00 True posterior myocardial infarction
66388 G33z000 Status anginosus
68357 G31y100 Microinfarction of heart
68401 Gyu3200 [X]Other forms of acute ischaemic heart 
disease
68748 G38z.00 Postoperative myocardial infarction, 
unspecified
72562 G353.00 Subsequent myocardial infarction of 
other sites
96838 Gyu3400 [X]Acute transmural myocardial 
infarction of unspecif site
99991 Gyu3600 [X]Subsequent myocardial infarction of 
unspecified site
105479 G39..00 Coronary microvascular disease
106812 G383.00 Postoperative transmural myocardial 
infarction unspec site
Heart Failure (QOF definition)
398 G580.00 Congestive heart failure
884 G581.00 Left ventricular failure
2062 G58..00 Heart failure
2906 G580.11 Congestive cardiac failure
13188 662G.00 Hypertensive treatm.changed
4024 G58z.00 Heart failure NOS
1223 G58..11 Cardiac failure
21826 662F.00 Hypertension treatm. started
5942 G581.13 Impaired left ventricular function
13189 662g.00 New York Heart Association classification 
- class II
12948 662H.00 Hypertension treatm.stopped
18853 662f.00 New York Heart Association classification 
- class I
19066 662h.00 New York Heart Association classification 
- class III
5255 G581000 Acute left ventricular failure
32671 G580100 Chronic congestive heart failure
10079 G580.12 Right heart failure
9524 G580.14 Biventricular failure
17278 G58z.12 Cardiac failure NOS
23707 G580000 Acute congestive heart failure
10154 G580.13 Right ventricular failure
27964 G582.00 Acute heart failure
27884 G580200 Decompensated cardiac failure
23481 G581.11 Asthma - cardiac
51214 662i.00 New York Heart Association classification 
- class IV
43618 G581.12 Pulmonary oedema - acute
11424 G580300 Compensated cardiac failure
22262 G1yz100 Rheumatic left ventricular failure
12590 G58z.11 Weak heart
101138 G583.00 Heart failure with normal ejection 
fraction
94870 G580400 Congestive heart failure due to valvular 
disease
104275 G584.00 Right ventricular failure
101137 G583.11 HFNEF - heart failure with normal 
ejection fraction
106897 G583.12
Ischaemic Stroke
5363 G64..11 CVA - cerebral artery occlusion
6155 G64..13 Stroke due to cerebral arterial occlusion
33543 G6X..00 Cerebrl infarctn due/unspcf occlusn or 
sten/cerebrl artrs
53745 Gyu6400 [X]Other cerebral infarction
40758 G6W..00 Cereb infarct due unsp occlus/stenos 
precerebr arteries
40053 G671.00 Generalised ischaemic cerebrovascular 
disease NOS
39403 G683.00 Sequelae of cerebral infarction
91627 Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or 
sten/cerebrl artrs
94482 Gyu6G00 [X]Cereb infarct due unsp occlus/stenos 
precerebr arteries
92036 Gyu6600 [X]Occlusion and stenosis of other 
cerebral arteries
90572 Gyu6500 [X]Occlusion and stenosis of other 
precerebral arteries
CKD stages 3-5 (QOF)
2994 7L1A100 Peritoneal dialysis
2996 7L1A200 Haemodialysis NEC
2997 7B00.00 Transplantation of kidney
5504 7B00z00 Transplantation of kidney NOS
5911 ZV42000 [V]Kidney transplanted
8037 7L1B000 Insertion of ambulatory peritoneal 
dialysis catheter
11553 SP08300 Kidney transplant failure and rejection
11745 7B00100 Transplantation of kidney from live 
donor
11773 7L1A.11 Dialysis for renal failure
12479 1Z13.00 Chronic kidney disease stage 4
12585 1Z14.00 Chronic kidney disease stage 5
18774 TB00111 Renal transplant with complication, 
without blame
20073 7L1A000 Renal dialysis
22252 ZV45100 [V]Renal dialysis status
23773 7L1B100 Removal of ambulatory peritoneal 
dialysis catheter
24361 7B00200 Transplantation of kidney from cadaver
26862 7B06300 Exploration of renal transplant
28158 TB11.00 Kidney dialysis with complication, 
without blame
30709 7L1C000 Insertion of temporary peritoneal dialysis 
catheter
30756 7L1A500 Continuous ambulatory peritoneal 
dialysis
36442 7L1B.11 Placement ambulatory dialysis apparatus 
- compens renal fail
45160 ZV56y11 [V]Aftercare involving peritoneal dialysis
46145 ZV56011 [V]Aftercare involving renal dialysis NOS
46438 SP05613 [X] Peritoneal dialysis associated 
peritonitis
48057 K0B5.00 Renal tubulo-interstitial disordrs in 
transplant rejectn
48121 7B01500 Transplant nephrectomy
48639 SP01500 Mechanical complication of dialysis 
catheter
54844 U612200 [X]Failure sterile precautions dur kidney 
dialys/other perf
54990 TB00100 Kidney transplant with complication, 
without blame
55151 7B00000 Autotransplant of kidney
59315 SP07G00 Stenosis of arteriovenous dialysis fistula
60446 Z919.00 Care of haemodialysis equipment
60498 Z919300 Reversing haemodialysis lines
medcode readcode readterm
60743 ZV56.00 [V]Aftercare involving intermittent 
dialysis
63038 ZV56z00 [V]Unspecified aftercare involving 
intermittent dialysis
63488 ZV56y00 [V]Other specified aftercare involving 
intermittent dialysis
63502 Z91A.00 Peritoneal dialysis bag procedure
64828 7L1A600 Peritoneal dialysis NEC
66705 7B00111 Allotransplantation of kidney from live 
donor
66714 TB11.11 Renal dialysis with complication, without 
blame
69266 TA22000 Failure of sterile precautions during 
kidney dialysis
69760 ZVu3G00 [X]Other dialysis
70874 7B00y00 Other specified transplantation of kidney
72004 7B01511 Excision of rejected transplanted kidney
72336 Z919100 Priming haemodialysis lines
88597 7L1A400 Automated peritoneal dialysis
89924 7B00300 Allotransplantation of kidney from 
cadaver, heart-beating
93366 7B0F.00 Interventions associated with 
transplantation of kidney
95122 1Z1H.00 Chronic kidney disease stage 4 with 
proteinuria
95405 1Z1L.00 Chronic kidney disease stage 5 without 
proteinuria
95406 1Z1J.00 Chronic kidney disease stage 4 without 
proteinuria
95508 1Z1K.00 Chronic kidney disease stage 5 with 
proteinuria
96133 7B00400 Allotransplantation kidney from cadaver, 
heart non-beating
96184 TA02000 Accid cut,puncture,perf,h'ge - kidney 
dialysis
96347 7A61900 Ligation of arteriovenous dialysis fistula
97587 1Z1J.11 CKD stage 4 without proteinuria
97683 1Z1L.11 CKD stage 5 without proteinuria
98364 7B00211 Allotransplantation of kidney from 
cadaver
99160 1Z1K.11 CKD stage 5 with proteinuria
99312 1Z1H.11 CKD stage 4 with proteinuria
104963 K054.00 Chronic kidney disease stage 4
105151 K055.00 Chronic kidney disease stage 5
Diabetic retinopathy
1323 F420.00 Diabetic retinopathy
1411 3128100 Fundoscopy abnormal
1438 F421000 Unspecified background retinopathy
2254 F424100 Central serous retinopathy
2986 F420200 Preproliferative diabetic retinopathy
3286 F420100 Proliferative diabetic retinopathy
3822 2BB8.00 O/E - vitreous haemorrhages
3837 F420400 Diabetic maculopathy
3914 2BB9.00 O/E - retinal pigmentation
4514 7270011 Anterior vitrectomy
6509 C108700 Insulin dependent diabetes mellitus with 
retinopathy
6702 F421300 Hypertensive retinopathy
6836 7271100 Laser photocoagulation of retina for 
detachment
7069 F420000 Background diabetic retinopathy
7890 F422.00 Other proliferative retinopathy
8595 F42y600 Retinal exudate or deposit
8742 2BB5.00 O/E - retinal haemorrhages
9318 7272300 Laser destruction of lesion of retina
9339 F421.00 Other background retinopathy
9835 2BBL.00 O/E - diabetic maculopathy present both 
eyes
10099 F420300 Advanced diabetic maculopathy
10755 F420600 Non proliferative diabetic retinopathy
10882 F421400 Exudative retinopathy
11053 F421800 Retinal microaneurysms NOS
11129 2BBQ.00 O/E - left eye background diabetic 
retinopathy
11433 2BBP.00 O/E - right eye background diabetic 
retinopathy
11626 F420z00 Diabetic retinopathy NOS
11858 7270400 Pars plana vitrectomy
11874 F422100 Proliferative retinopathy due to sickle 
cell disease
11912 5B4..11 Retinal laser therapy
13097 2BBT.00 O/E - right eye proliferative diabetic 
retinopathy
13099 2BBR.00 O/E - right eye preproliferative diabetic 
retinopathy
13101 2BBV.00 O/E - left eye proliferative diabetic 
retinopathy
13102 2BBW.00 O/E - right eye diabetic maculopathy
13103 2BBS.00 O/E - left eye preproliferative diabetic 
retinopathy
13106 2BB6.00 O/E - retinal exudates
13107 2BBn.00 O/E - left eye clinically significant 
macular oedema
13108 2BBX.00 O/E - left eye diabetic maculopathy
17262 C109600 Non-insulin-dependent diabetes mellitus 
with retinopathy
17293 727..00 Retina and other parts of eye operations
17916 F422011 Retinopathy of prematurity
18387 C10E700 Type 1 diabetes mellitus with 
retinopathy
18496 C10F600 Type 2 diabetes mellitus with 
retinopathy
18775 2BBO.00 O/E - Laser photocoagulation scars
19532 2BB4.00 O/E - retinal microaneurysms
19533 2BBY.00 O/E - referable retinopathy
22871 C10EP00 Type 1 diabetes mellitus with exudative 
maculopathy
medcode readcode readterm
22967 2BBF.00 Retinal abnormality - diabetes related
25591 C10FQ00 Type 2 diabetes mellitus with exudative 
maculopathy
25888 2BBm.00 O/E - right eye clinically significant 
macular oedema
27022 5B42.00 Laser therapy - retinal lesion
30477 F420700 High risk proliferative diabetic 
retinopathy
31829 F433100 Solar retinopathy
34455 F421112 Atheroscleritic retinopathy
35659 2BB7.00 O/E - retinal vascular prolif.
36035 F422y00 Other specified other proliferative 
retinopathy
36119 F421111 Arterosclerotic retinopathy
36855 2BBG.00 Retinal abnormality - non-diabetes
36867 2BBa.00 O/E- non-referable retinopathy
38096 F422z00 Proliferative retinopathy NOS
38161 C108711 Type I diabetes mellitus with retinopathy
39457 F421C00 Other intraretinal microvascular 
abnormality
40982 F421z00 Other background retinopathy NOS
41049 C108712 Type 1 diabetes mellitus with 
retinopathy
41229 F421100 Atherosclerotic retinopathy
42762 C109612 Type 2 diabetes mellitus with 
retinopathy
45145 2BB2.00 O/E - retinal vessel narrowing
45876 F421200 Renal retinopathy
46068 7272500 Panretinal laser photocoagulation to 
lesion of retina NEC
47328 2BBk.00 O/E - right eye stable treated prolif 
diabetic retinopathy
48751 2BB3.00 O/E - retinal A-V nipping
49655 C10F611 Type II diabetes mellitus with 
retinopathy
50656 2BBc.00 O/E - No retinal laser photocoagulation 
scars
52041 2BBl.00 O/E - left eye stable treated prolif 
diabetic retinopathy
52630 2BBo.00 O/E - sight threatening diabetic 
retinopathy
55026 7270B11 Anterior vitrectomy
58604 C109611 Type II diabetes mellitus with 
retinopathy
65463 F420800 High risk non proliferative diabetic 
retinopathy
66964 F426500 Pseudoretinitis pigmentosa
69662 F421G00 Venostasis retinopathy
72424 7270B00 Vitrectomy using anterior approach
86068 7272800 Panretinal laser photocoagulation to 
lesion of retina
88368 7270411 Vitrectomy using pars plana approach
93875 C10E712 Insulin dependent diabetes mellitus with 
retinopathy
95343 C10E711 Type I diabetes mellitus with retinopathy
96926 FyuF700 [X]Other proliferative retinopathy
97894 C10EP11 Type I diabetes mellitus with exudative 
maculopathy
100979 7272900 Focal laser photocoagulation of retina
101881 2BBr.00 Impaired vision due to diabetic 
retinopathy
102242 2BBs.00 Retinal arteries silverwire
Neuropathy
2342 F372.12 Diabetic neuropathy
2790 F367.00 Peripheral neuropathy
2925 F375.00 Alcoholic polyneuropathy
3958 F366.00 Polyneuropathy
5002 F372.11 Diabetic polyneuropathy
6908 F36yz00 Other idiopathic peripheral neuropathy 
NOS
7635 F362.00 Hereditary sensory neuropathy
7795 C106.12 Diabetes mellitus with neuropathy
8591 F35z.11 Peripheral neuropathy - hereditary or 
idiopathic
9193 F336.00 Phantom limb syndrome
10722 F37..00 Inflammatory and toxic neuropathy
11544 N242300 Neuropathic pain
11663 M271100 Neuropathic diabetic ulcer - foot
14883 F36z.00 Hereditary or idiopathic peripheral 
neuropathy NOS
14884 F36y.00 Other idiopathic peripheral neuropathy
15481 F37z.00 Toxic or inflammatory neuropathy NOS
16230 C106.00 Diabetes mellitus with neurological 
manifestation
16491 C106.13 Diabetes mellitus with polyneuropathy
18016 F336000 Phantom limb syndrome with pain
18075 F36..00 Hereditary and idiopathic peripheral 
neuropathy
18425 C10FB00 Type 2 diabetes mellitus with 
polyneuropathy
18534 F342400 Ulnar neuropathy
19454 F374A00 Polyneuropathy in uraemia
22573 C106z00 Diabetes mellitus NOS with neurological 
manifestation
24121 F378.00 Intercostal neuropathy
24216 F370100 Postinfectious polyneuritis
24222 F376.00 Polyneuropathy due to drugs
24226 F37z.11 Polyneuropathy unspecified
24355 F374200 Polyneuropathy in vitamin B deficiency
24571 F372200 Asymptomatic diabetic neuropathy
24694 C108B00 Insulin dependent diabetes mellitus with 
mononeuropathy
28333 C373200 Familial neuropathic amyloid
30537 F373.00 Polyneuropathy in malignant disease
31551 F37X.00 Inflammatory polyneuropathy, 
unspecified
31790 F372.00 Polyneuropathy in diabetes
32527 F368.00 Hereditary motor and sensory 
neuropathy
34268 C10F200 Type 2 diabetes mellitus with 
neurological complications
35465 F368100 Hereditary motor and sensory 
neuropathy type II
35537 Fyu7C00 [X] Polyneuropathy, unspecified
35785 F372100 Chronic painful diabetic neuropathy
36643 N035.12 Neuropathic arthritis
37315 F3y0.00 Diabetic mononeuropathy
38401 F360z00 Hereditary peripheral neuropathy NOS
39317 C106100 Diabetes mellitus, adult onset, + 
neurological manifestation
39528 F360.00 Hereditary peripheral neuropathy
39858 Fyu7B00 [X]Inflammatory polyneuropathy, 
unspecified
40751 F374900 Polyneuropathy in sarcoidosis
41652 F37y.00 Other toxic or inflammatory neuropathy
41716 C108C00 Insulin dependent diabetes mellitus with 
polyneuropathy
42831 C10E200 Type 1 diabetes mellitus with 
neurological complications
44095 F371000 Polyneuropathy in disseminated lupus 
erythematosus
44512 F364.00 Idiopathic progressive polyneuropathy
45081 F37..11 Toxic neuropathy
45467 C109B00 Non-insulin dependent diabetes mellitus 
with polyneuropathy
45919 C109212 Type 2 diabetes mellitus with 
neurological complications
46301 C10EC00 Type 1 diabetes mellitus with 
polyneuropathy
46937 F365.00 Neuropathy in association with 
hereditary ataxia
47409 C109B11 Type II diabetes mellitus with 
polyneuropathy
47465 F371100 Polyneuropathy in polyarteritis nodosa
49146 C108211 Type I diabetes mellitus with 
neurological complications
50527 C10FB11 Type II diabetes mellitus with 
polyneuropathy
50813 C109A11 Type II diabetes mellitus with 
mononeuropathy
52089 F374300 Polyneuropathy in diphtheria
52283 C108200 Insulin-dependent diabetes mellitus with 
neurological comps
54124 F377.00 Other toxic agent polyneuropathy
55076 Fyu7.00 [X]Polyneuropathies & other disord of 
peripheral nerv syst
55842 C109200 Non-insulin-dependent diabetes mellitus 
with neuro comps
56159 Z6P2100 Control of phantom sensation technique
56272 F374.00 Polyneuropathy in disease EC
56910 F368000 Hereditary motor and sensory 
neuropathy type I
57313 F371.00 Polyneuropathy in collagen vascular 
disease
58758 F374800 Polyneuropathy in porphyria
59903 C106.11 Diabetic amyotrophy
medcode readcode readterm
61523 C106y00 Other specified diabetes mellitus with 
neurological comps
61829 C108212 Type 1 diabetes mellitus with 
neurological complications
62401 F371200 Polyneuropathy in rheumatoid arthritis
62674 C10FA00 Type 2 diabetes mellitus with 
mononeuropathy
63555 F374z00 Polyneuropathy in disease NOS
66336 F374000 Polyneuropathy in amyloidosis
67853 C106000 Diabetes mellitus, juvenile, + 
neurological manifestation
67905 C109211 Type II diabetes mellitus with 
neurological complications
68105 C10EB00 Type 1 diabetes mellitus with 
mononeuropathy
68960 F374500 Polyneuropathy in hypoglycaemia
69047 F37y000 Serum neuropathy
71258 F371z00 Polyneuropathy in collagen vascular 
disease NOS
72320 C109A00 Non-insulin dependent diabetes mellitus 
with mononeuropathy
72922 Fyu6B00 [X]Other mononeuropathies of lower 
limb
73337 F374100 Polyneuropathy in beriberi
91741 Fyu6C00 [X]Other specified mononeuropathies
91943 C10EC11 Type I diabetes mellitus with 
polyneuropathy
93228 Fyu1300 [X]Paraneoplastic neuromyopathy and 
neuropathy
93868 Fyu6A00 [X]Other mononeuropathies of upper 
limb
95351 C10FA11 Type II diabetes mellitus with 
mononeuropathy
96256 F37y100 Axonal sensorimotor neuropathy
97306 Fyu7200 [X]Other specified polyneuropathies
97449 Fyu7000 [X]Other hereditary and idiopathic 
neuropathies
97479 Fyu7100 [X]Other inflammatory polyneuropathies
97848 A72x100 Mumps polyneuropathy
98616 C10F211 Type II diabetes mellitus with 
neurological complications
99231 C108B11 Type I diabetes mellitus with 
mononeuropathy
99855 M271700 Neuropathic foot ulcer
100064 F374600 Polyneuropathy in mumps
101311 C10EC12 Insulin dependent diabetes mellitus with 
polyneuropathy
101735 C10E212 Insulin-dependent diabetes mellitus with 
neurological comps
105825 C373K13 Familial amyloid polyneuropathy type III
106103 F368200 Hereditary motor and sensory 
neuropathy type III
107322 Fyu6D00 [X]Other mononeuropathies in diseases 
classified elsewhere
Hypertension (QOF)
204 G2...00 Hypertensive disease
799 G20..00 Essential hypertension
351 G20..11 High blood pressure
15377 G200.00 Malignant essential hypertension
1894 G201.00 Benign essential hypertension
4372 G202.00 Systolic hypertension
83473 G203.00 Diastolic hypertension
10818 G20z.00 Essential hypertension NOS
3712 G20z.11 Hypertension NOS
7329 G24..00 Secondary hypertension
31755 G240.00 Secondary malignant hypertension
73293 G240z00 Secondary malignant hypertension NOS
57288 G241.00 Secondary benign hypertension
51635 G241z00 Secondary benign hypertension NOS
34744 G244.00 Hypertension secondary to endocrine 
disorders
16059 G24z.00 Secondary hypertension NOS
31387 G24z000 Secondary renovascular hypertension 
NOS
42229 G24zz00 Secondary hypertension NOS
69753 Gyu2.00 [X]Hypertensive diseases
102458 Gyu2000 [X]Other secondary hypertension
Pre-diabetes
10921 C11y200 Impaired glucose tolerance
10983 C11y300 Impaired fasting glycaemia
106604 C11y500 Pre-diabetes
10042 R10E.00 [D]Impaired glucose tolerance
10791 R10D000 [D]Impaired fasting glycaemia
31161 R10D011 [D]Impaired fasting glucose
11149 R102.11 [D]Prediabetes
11818 R102.00 [D]Glucose tolerance test abnormal
Gestational diabetes 
10278 L180800 Diabetes mellitus arising in pregnancy
8446 L180811 Gestational diabetes mellitus
2664 L180900 Gestational diabetes mellitus
Family history of diabetes
23005 1253 FH: Diabetes mellitus in first degree 
relative
6795 1252 FH: Diabetes mellitus
Family history of CVD
2973 ZV17312 [V]Family history of myocardial infarction
3198 12C2.00 FH: Ischaemic heart dis. <60
5970 ZV17311 [V]Family history of ischaemic heart 
disease (IHD)
6323 12C4.12 FH: Stroke
6324 12C5.00 FH: Myocardial infarction
6784 12C..13 FH: Heart disorder
7207 12C3.13 FH: Angina > 60yrs
7765 12C4.11 FH: CVA
8223 12C3.00 FH: Ischaemic heart dis. >60
8258 12C4.00 FH: CVA/stroke
9398 1225.00 No FH: Stroke/TIA
9490 12C5.12 FH: Ischaemic heart disease
9528 1226.11 No FH: Angina
9576 12C..11 FH: CVS disorder
10934 12C5.11 FH: Coronary thrombosis
11135 ZV17300 [V]Family history of ischaemic heart 
disease
11799 1226.00 No FH: Ischaemic heart disease
12089 12C3.12 FH: MI- myocardial infarct >60
12572 1225.11 No FH: CVA/Stroke/TIA
12709 12C2.13 FH: Angina < 60yrs
12806 12C2.12 FH: MI- Myocardial infarct <60
13222 12C..14 FH: Angina
13249 12C..12 FH: Cardiac disorder
13253 ZV17100 [V]Family history of stroke 
(cerebrovascular)
13258 12C..00 FH: Cardiovascular disease
13261 12C8.00 FH: Congenital heart disease
13269 12CA.00 FH myocardial infarction male first 
degree age known
13270 12C2.11 FH: Myocardial infarction < 60
13274 12CJ.00 FH: Cardiomyopathy
13275 12CQ.00 Family history of deep vein thrombosis
18661 12CP.00 FH: Myocardial infarct in 1st degree male 
relative <55 years
18997 12C7.00 Family history of transient ischaemic 
attack
19127 12CN.00 FH: Myocardial infarct in 1st degree 
female relative <65 yrs
19560 12C3.11 FH: Myocardial infarction > 60
19561 12C7.11 FH: TIA
19566 1224.00 No FH: Cardiovascular disease
23000 12CZ.00 FH: CVS disease NOS
26625 12J3.11 FH: Congenital heart disease
26636 12CE.00 FH angina male first degree age known
26637 12CC.00 FH myocardial infarction female first 
degree age known
26639 12CK.00 FH: Aortic aneurysm
26653 12CM.00 FH: Angina in 1st degree male relative 
<55 years
28347 12CI.00 FH: premature coronary heart disease
29064 ZV17111 [V]Family history of cerebrovascular 
accident (CVA)
30256 ZV17400 [V]Family history of other cardiovascular 
disease
30789 12CL.00 FH: Angina in 1st degree female relative 
<65 years
34500 12J3.00 FH: Congenital CVS anomaly
39572 12CB.00 FH myocardial infarction male first 
degree age unknown
40865 12CF.00 FH angina male first degree age 
unknown
42996 12CH.00 FH angina female first degree age 
unknown
43954 12CD.00 FH myocardial infarction female first 
degree age unknown
52870 ZVu6600 [X]Family hist/ischaemic hrt disease+oth 
dis/circultr system
88482 12CS.00 FH: Anomalous coronary artery
96212 12CV.00 FH: Cardiovascular disease 1st degree 
male relative < 55 yrs
96596 12CW.00 FH: Cardiovascular disease 1st degree 
female reltve < 65 yrs
103601 12CX.00 Family history of thromboembolic 
disorder
106585 12CY.00 FH: peripheral vascular disease
107341 12Ca.00 FH: Long QT syndrome
CVD Risk Score
7913 Coronary heart disease risk
10128 Cardiovascular event risk
10302 Framingham coronary heart disease 10 
year risk score
13283 Coronary heart disease risk
18581 Low risk of primary heart disease
18948 Moderate risk of primary heart disease
22210 High risk of primary heart disease
24721 Framingham coronary heart disease 10 
year risk score
26627 At risk of heart disease
29433 High risk of heart disease
36908 UKPDS 10yr coronary heart disease risk 
score
43934 Joint British Societies cardiac risk score
43938 Framingham coronary heart disease 10 
yr adjusted risk score
55103 JBS cardiovascular disease risk 10-20% 
over next 10 years
55104 JBS cardiovascular disease risk <10% over 
next 10 years
55105 JBS cardiovascular disease risk >30% over 
next 10 years
55109 JBS cardiovascular disease risk >20% up 
to 30% ov next 10 yr
71748 Coronary heart disease risk clinical 
management plan
85854 Review of patient at risk from coronary 
heart disease
95889 Assessing cardiovascular risk using SIGN 
score
QDiabetes Risk score
106622 38Gj.00 QDiabetes risk calculator
99822 38DK.00 Finnish diabetes risk score
107554 38Gv.00 Diabetes UK diabetes risk score
NHS Health Check
106237 9mC3.00 NHS Health Check invitation third letter
100682 9NiS.00 Did not attend NHS Health Check
105569 8BAg000 NHS Health Check completed by third 
party
106223 9mC4.00 NHS Health Check verbal invitation
106361 8IEd.00 NHS Health Check annual review 
declined
107476 9NSH.00 NHS Health Check not appropriate
107003 9RL0.00 NHS continuing healthcare checklist 
completed
110462 9mC6.00 NHS Health Check invitation SMS text 
message
106222 9mC0.00 NHS Health Check telephone invitation
102360 6AH..00 NHS Health Check annual review
106215 9mC..00 NHS Health Check invitation
100460 9Nj5.00 Failed to respond to NHS Health Check 
invitation
99856 8BAg.00 NHS Health Check completed
102511 8IAx.00 NHS Health Check declined
106961 9Nie.00 Did not attend NHS Health Check annual 
review
106217 9mC1.00 NHS Health Check invitation first letter
100000 8BR2.00 NHS Health Check indicated
106221 9mC2.00 NHS Health Check invitation second 
letter
100142 6B5..00 NHS Health Check programme
108311 8HBR.00 NHS Health Check follow up
110509 9mC5.00 NHS Health Check invitation email
Bacterial infections (UTI, LRTI, 
cellulitis)
150 K190z00 urinary tract infection, site not specified 
nos
389 K15..00 cystitis
1289 K190.00 urinary tract infection, site not specified
7579 1J4..00 suspected uti
10857 K15y.00 other specified cystitis
12484 K15z.00 cystitis nos
15074 K150.00 acute cystitis
34630 K15yz00 other cystitis nos
70189 Kyu5100 [x]other cystitis
97002 K190500 urinary tract infection
104141 K190600 urosepsis
medcode readcode readterm
68 H06z011 chest infection
312 H060.00 acute bronchitis
572 H26..00 pneumonia due to unspecified organism
886 H25..00 bronchopneumonia due to unspecified 
organism
1382 H060w00 acute viral bronchitis unspecified
1934 H301.00 laryngotracheobronchitis
2581 H06z000 chest infection nos
3163 H300.00 tracheobronchitis nos
3358 H06z100 lower resp tract infection
3480 H30z.00 bronchitis nos
3683 H261.00 basal pneumonia due to unspecified 
organism
5978 H060.11 acute wheezy bronchitis
6094 H2z..00 pneumonia or influenza nos
6124 H062.00 acute lower respiratory tract infection
9389 H20..11 chest infection - viral pneumonia
9639 H260.00 lobar pneumonia due to unspecified 
organism
11072 H060300 acute purulent bronchitis
11101 H060500 acute tracheobronchitis
14976 H20z.00 viral pneumonia nos
16287 H25..11 chest infection - unspecified 
bronchopneumonia
17359 H30..11 chest infection - unspecified bronchitis
19400 H26..11 chest infection - pnemonia due to 
unspecified organism
20198 H060z00 acute bronchitis nos
21061 H3y0.00 chronic obstruct pulmonary dis with 
acute lower resp infectn
22795 H22..11 chest infection - other bacterial 
pneumonia
23095 H22z.00 bacterial pneumonia nos
23333 H540000 hypostatic pneumonia
24356 H540100 hypostatic bronchopneumonia
24800 H060x00 acute bacterial bronchitis unspecified
28634 H22..00 other bacterial pneumonia
30653 H23..11 chest infection - pneumonia organism os
33478 H20y.00 viral pneumonia nec
37447 H06z112 acute lower respiratory tract infection
40498 H24..00 pneumonia with infectious diseases ec
43884 H22yz00 pneumonia due to bacteria nos
50867 H22y.00 pneumonia due to other specified 
bacteria
52520 Hyu0800 [x]other viral pneumonia
53753 Hyu0H00 [x]other pneumonia, organism 
unspecified
63763 Hyu0A00 [x]other bacterial pneumonia
66362 H24z.00 pneumonia with infectious diseases ec 
nos
66397 Hyu1.00 [x]other acute lower respiratory 
infections
69782 H24y.00 pneumonia with other infectious 
diseases ec
70559 H24yz00 pneumonia with other infectious 
diseases ec nos
98381 Hyu0B00 [x]pneumonia due to other specified 
infectious organisms
104121 H2B..00 community acquired pneumonia
4126 A98yy14 Gonococcal cellulitis
4328 F4G0100 Orbital cellulitis
8852 F501112 Cellulitis, external ear
25156 H1y2100 Pharynx or nasopharynx cellulitis
64484 H1y5100 Cellulitis of vocal cords
61518 H1y7100 Cellulitis of larynx
4748 J083.00 Oral cellulitis and abscess
5228 J083000 Cellulitis of floor of mouth
15336 J083100 Oral soft tissue cellulitis unspecified
19944 J083z00 Oral cellulitis and abscess NOS
17562 J085100 Cellulitis of lip
27933 J54..11 Cellulitis - anus or rectum
37424 J540.11 Perianal cellulitis
26239 K170300 Periurethral cellulitis
16304 K272300 Cellulitis of penis
4456 K284300 Cellulitis of scrotum
70783 K403.00 Acute parametritis and pelvic cellulitis
33659 K403100 Acute pelvic cellulitis
48663 K404.00 Chronic parametritis and pelvic cellulitis
24294 K404000 Chronic female pelvic cellulitis
15687 K405.00 Parametritis and pelvic cellulitis 
unspecified
30982 K405100 Pelvic cellulitis unspecified
5697 M02..00 Cellulitis and abscess of finger and toe
4779 M020.00 Cellulitis and abscess of finger
3527 M020000 Cellulitis and abscess of finger 
unspecified
26071 M020z00 Cellulitis and abscess of finger NOS
3960 M021.00 Cellulitis and abscess of toe
3363 M021000 Cellulitis and abscess of toe unspecified
20384 M021z00 Cellulitis and abscess of toe NOS
25081 M02z.00 Cellulitis and abscess of digit NOS
16536 M03..00 Other cellulitis and abscess
16606 M03..13 Cellulitis of skin area excluding digits of 
hand or foot
3998 M030.00 Cellulitis and abscess of face
24401 M030000 Cellulitis and abscess of cheek (external)
2658 M030011 Cellulitis and abscess of cheek
21580 M030100 Cellulitis and abscess of nose (external)
10485 M030111 Cellulitis and abscess of nose
15549 M030200 Cellulitis and abscess of chin
15327 M030300 Cellulitis and abscess of submandibular 
region
15475 M030400 Cellulitis and abscess of forehead
16032 M030500 Cellulitis and abscess of temple region
27681 M030600 Cellulitis of face
20389 M030z00 Cellulitis and abscess of face NOS
2711 M031.00 Cellulitis and abscess of neck
27717 M032.00 Cellulitis and abscess of trunk
4394 M032000 Cellulitis and abscess of chest wall
16176 M032100 Cellulitis and abscess of breast
1874 M032200 Cellulitis and abscess of back
4973 M032300 Cellulitis and abscess of abdominal wall
14937 M032400 Cellulitis and abscess of umbilicus
23585 M032500 Cellulitis and abscess of flank
1923 M032600 Cellulitis and abscess of groin
4400 M032700 Cellulitis and abscess of perineum
52366 M032800 Cellulitis of trunk
29345 M084.00 [X]Cellulitis of breast
6368 M085.00 Cellulitis of leg
31534 M086.00 Cellulitis of ankle
9648 M088.00 Cellulitis of arm
28181 M089.00 Cellulitis of neck
17226 M08A.00 Cellulitis of axilla
7684 M08B.00 Cellulitis of foot
94868 M08C.00 Cellulitis of toe
30260 M08y.00 [X]Cellulitis of other sites
Structured diabetes 
programme
93854 9OLM.00 Diabetes structured education 
programme declined
26605 9OLB.00 Attended diabetes structured education 
programme
47011 8Hj0.00 Referral to diabetes structured education 
programme
107414 8I94.00 Diabetes structured education 
programme not available
95093 8I83.00 Did not complete DESMOND diabetes 
structured educat program
94956 8I84.00 Did not complete XPERT diabetes 
structured education program
97809 8I82.00 Did not complete DAFNE diabetes 
structured education program
95641 8Hj1.00 Family/carer referral to diabetes 
structured education prog
94955 9NiE.00 Did not attend XPERT diabetes 
structured education programme
93631 9OLL.00 XPERT diabetes structured education 
programme completed
110511 67W1.00 Recommendation self-refer for diabetes 
structured education
106953 8IEa.00 Referral to DAFNE diabetes structured 
educn prog declined
95094 8I81.00 Did not complete diabetes structured 
education programme
93491 9OLJ.00 DAFNE diabetes structured education 
programme completed
95159 9NiD.00 Did not attend DESMOND diabetes 
structured education program
93870 8Hj5.00 Referral to XPERT diabetes structured 
education programme
94011 9OLG.00 Attended XPERT diabetes structured 
education programme
99277 9NiC.00 Did not attend DAFNE diabetes 
structured education programme
93657 8Hj4.00 Referral to DESMOND diabetes 
structured education programme
12682 679R.00 Patient offered diabetes structured 
education programme
51066 9OLC.00 Family/carer attended diabetes 
structured education prog
93390 9OLH.00 Attended DAFNE diabetes structured 
education programme
94186 9OLF.00 Diabetes structured education 
programme completed
93704 8Hj3.00 Referral to DAFNE diabetes structured 
education programme
95553 9NiA.00 Did not attend diabetes structured 
education programme
93529 9OLK.00 DESMOND diabetes structured education 
programme completed
Diabetes review
6125 66AS.00 Diabetic annual review
11471 8B3l.00 Diabetes medication review
28873 66Ai.00 Diabetic 6 month review
32619 66Af.00 Patient diabetes education review
83532 66Ao.00 Diabetes type 2 review
101177 66At.00 Diabetic dietary review
101801 66At100 Type II diabetic dietary review
102434 66Au.00 Diabetic erectile dysfunction review
102611 66At111 Type 2 diabetic dietary review
107423 661N400 Diabetes self-management plan review
107464 66AS000 Diabetes Year of Care annual review
Retinopathy screening/review
18662 8HBH.00 Diabetic retinopathy 6 month review
18311 68A7.00 Diabetic retinopathy screening
11891 68A8.00 Digital retinal screening
9974 9N1v.00 Seen in diabetic eye clinic
12636 9N2f.00 Seen by retinal screener
18747 8I6F.00 Diabetic retinopathy screening not 
indicated
12262 8I3X.00 Diabetic retinopathy screening refused
Diabetic foot screening
22823 66Ab.00 Diabetic foot examination
95994 66Aq.00 Diabetic foot screen
50175 66AW.00 Diabetic foot risk assessment
108890 679L300 Diabetic foot care education
18824 8I3W.00 Diabetic foot examination declined
12247 8I6G.00 Diabetic foot examination not indicated
10824 9N1i.00 Seen in diabetic foot clinic
 Table S5. Code lists
